

**FACT SHEET FOR HEALTHCARE PROVIDERS ADMINISTERING  
VACCINE (VACCINATION PROVIDERS)  
EMERGENCY USE AUTHORIZATION (EUA) OF  
THE MODERNA COVID-19 VACCINE TO PREVENT CORONAVIRUS DISEASE 2019  
(COVID-19)**

**PRIMARY SERIES AND BOOSTER DOSE PRESENTATION**  
**Primary Series Doses for 12 Years and Older**  
**Booster Doses for 18 Years and Older<sup>1</sup>**

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product, MODERNA COVID-19 VACCINE, for active immunization to prevent COVID-19 in individuals 6 months of age and older.

This Fact Sheet pertains only to Moderna COVID-19 Vaccine supplied in a multiple-dose vial with a red cap and a label with a light blue border which is authorized for use to provide:

- a two-dose primary series to individuals 12 years of age and older;
- a third primary series dose to individuals 12 years of age and older with certain kinds of immunocompromise;<sup>2</sup>
- a first booster dose to individuals 18 years of age and older who have completed a primary series with Moderna COVID-19 Vaccine or SPIKEVAX (COVID-19 Vaccine, mRNA);
- a first booster dose to individuals 18 years of age and older who have completed primary vaccination with another authorized or approved COVID-19 vaccine. The dosing interval for the heterologous booster dose is the same as that authorized for a booster dose of the vaccine used for primary vaccination;
- a second booster dose to individuals 50 years of age and older who have received a first booster dose of any authorized or approved COVID-19 vaccine; and
- a second booster dose to individuals 18 years of age and older with certain kinds of immunocompromise and who have received a first booster dose of any authorized or approved COVID-19 vaccine.

---

<sup>1</sup> Another presentation of Moderna COVID-19 Vaccine supplied in multiple-dose vials with dark blue caps and labels with a purple border can be used for a booster dose for individuals 18 years of age and older. The Moderna COVID-19 Vaccine supplied in multiple-dose vials with dark blue caps and labels with a purple border and the Moderna COVID-19 Vaccine supplied in multiple-dose vials with red caps and labels with a light blue border contain the same ingredients. The concentrations of some of the ingredients differ between the two presentations. Ingredient information for each presentation is included in the Description section of the respective Full EUA Prescribing Information.

<sup>2</sup> Certain kinds of immunocompromise refers to individuals who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.

**SPIKEVAX (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by ModernaTX, Inc. that is indicated for active immunization to prevent COVID-19 in individuals 18 years of age and older.<sup>3</sup> It is approved for use as a two-dose primary series for the prevention of COVID-19 in individuals 18 years of age and older. It is also authorized for emergency use to provide:**

- **a two-dose primary series to individuals 12 years through 17 years of age;**
- **a third primary series dose to individuals 12 years of age and older with certain kinds of immunocompromise;**
- **a first booster dose to individuals 18 years of age and older who have completed a primary series with Moderna COVID-19 Vaccine or SPIKEVAX (COVID-19 Vaccine, mRNA);**
- **a first booster dose to individuals 18 years of age and older who have completed primary vaccination with another authorized or approved COVID-19 vaccine. The dosing interval for the heterologous booster dose is the same as that authorized for a booster dose of the vaccine used for primary vaccination;**
- **a second booster dose to individuals 50 years of age and older who have received a first booster dose of any authorized or approved COVID-19 vaccine; and**
- **a second booster dose to individuals 18 years of age and older with certain kinds of immunocompromise and who have received a first booster dose of any authorized or approved COVID-19 vaccine.**

---

<sup>3</sup> As described in the Letter of Authorization, the FDA-approved SPIKEVAX (COVID-19 Vaccine, mRNA) and the EUA-authorized presentations of the Moderna COVID-19 Vaccine supplied in multiple-dose vials with red caps and labels with a light blue border and multiple-dose vials with dark blue caps and labels with a purple border can be used to provide booster doses to individuals 18 years of age and older. The FDA-approved SPIKEVAX (COVID-19 Vaccine, mRNA) and the EUA-authorized presentation of the Moderna COVID-19 Vaccine supplied in multiple-dose vials with red caps and labels with a light blue border can be used interchangeably to provide primary series doses to individuals 12 years of age and older and booster doses to individuals 18 years of age and older without presenting any safety or effectiveness concerns.

**SPIKEVAX (COVID-19, mRNA) and Moderna COVID-19 Vaccine supplied in multiple-dose vials with a red cap and a label with a light blue border intended for use in individuals 12 years of age and older should not be used in individuals 6 months through 11 years of age because of the potential for vaccine administration errors, including dosing errors.<sup>4,5</sup>**

## **SUMMARY OF INSTRUCTIONS FOR COVID-19 VACCINATION PROVIDERS**

Vaccination providers enrolled in the federal COVID-19 Vaccination Program must report all vaccine administration errors, all serious adverse events, cases of Multisystem Inflammatory Syndrome (MIS) in adults and children, and cases of COVID-19 that result in hospitalization or death following administration of the Moderna COVID-19 Vaccine. See “MANDATORY REQUIREMENTS FOR MODERNA COVID-19 VACCINE ADMINISTRATION UNDER EMERGENCY USE AUTHORIZATION” for reporting requirements.

The Moderna COVID-19 Vaccine is a suspension for intramuscular injection.

### Primary Series<sup>6</sup>

Each primary series dose of the Moderna COVID-19 Vaccine for individuals 12 years of age and older is 0.5 mL.

The Moderna COVID-19 Vaccine supplied in a multiple-dose vial with a red cap and a label with a light blue border is administered as a primary series of two doses (0.5 mL each) 1 month apart to individuals 12 years of age or older.

A third primary series dose (0.5 mL) of the Moderna COVID-19 Vaccine supplied in a multiple-dose vial with a red cap and a label with a light blue border is authorized for administration at least 1 month following the second dose to individuals at least 12 years of age with certain kinds of immunocompromise.

---

<sup>4</sup> Notwithstanding the age limitations for use of the different presentations of the Moderna COVID-19 Vaccine, individuals who will turn from 11 years to 12 years of age between doses in the primary series may receive, for any dose in the primary series, either: (1) the Moderna COVID-19 Vaccine authorized for use in individuals 6 years through 11 years of age (each 0.5 mL dose containing 50 mcg mRNA) supplied in multiple-dose vials with dark blue caps and labels with a purple border stating “BOOSTER DOSES ONLY”; (2) SPIKEVAX (COVID-19 Vaccine, mRNA) or the Moderna COVID-19 Vaccine authorized for use in individuals 12 years of age and older (each 0.5 mL dose containing 100 mcg mRNA) supplied in multiple-dose vials with red caps and labels with a light blue border; or (3) the Moderna COVID-19 Vaccine authorized for use in individuals 6 years through 11 years of age (each 0.5 mL dose containing 50 mcg mRNA) supplied in multiple-dose vials with dark blue caps and labels with a teal border (currently not available). The multiple-dose vials with dark blue caps and labels with a purple border are authorized to provide 0.5 mL primary series doses for individuals 6 years through 11 years of age and to provide 0.5 mL booster doses for individuals 18 years of age and older.

<sup>5</sup> For primary vaccination of individuals 6 months through 5 years of age and 6 years through 11 years of age, refer to the respective Moderna COVID-19 Vaccine Fact Sheet for Healthcare Providers Administering Vaccine.

<sup>6</sup> A primary series dose of SPIKEVAX (COVID-19 Vaccine, mRNA) is 0.5 mL.

## Booster Doses<sup>7,8</sup>

### *First Booster Dose*

A first booster dose (0.25 mL) of the Moderna COVID-19 Vaccine supplied in a multiple-dose vial with a red cap and a label with a light blue border may be administered at least 5 months after completing a primary series of the Moderna COVID-19 Vaccine or SPIKEVAX (COVID-19 Vaccine, mRNA) to individuals 18 years of age or older.

A first booster dose (0.25 mL) of the Moderna COVID-19 Vaccine supplied in a multiple-dose vial with a red cap and a label with a light blue border may be administered to individuals 18 years of age and older as a heterologous booster dose following completion of primary vaccination with another authorized or approved COVID-19 vaccine. The dosing interval for the heterologous booster dose is the same as that authorized for a booster dose of the vaccine used for primary vaccination.

### *Second Booster Dose*

A second booster dose (0.25 mL) of the Moderna COVID-19 Vaccine supplied in a multiple-dose vial with a red cap and a label with a light blue border may be administered to individuals 50 years of age and older at least 4 months after receipt of a first booster dose of any authorized or approved COVID-19 vaccine.

A second booster dose (0.25 mL) of the Moderna COVID-19 Vaccine supplied in a multiple-dose vial with a red cap and a label with a light blue border may be administered at least 4 months after receipt of a first booster dose of any authorized or approved COVID-19 vaccine to individuals 18 years of age and older with certain kinds of immunocompromise.

See this Fact Sheet for instructions for preparation and administration. This Fact Sheet may have been updated. For the most recent Fact Sheet, please see [www.modernatx.com/covid19vaccine-eua](http://www.modernatx.com/covid19vaccine-eua).

For information on clinical trials that are testing the use of the Moderna COVID-19 Vaccine for active immunization against COVID-19, please see [www.clinicaltrials.gov](http://www.clinicaltrials.gov).

## **DESCRIPTION OF COVID-19**

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the novel coronavirus, SARS-CoV-2, that appeared in late 2019. It is predominantly a respiratory illness that can affect other organs. People with COVID-19 have reported a wide range of symptoms, ranging from mild symptoms to severe illness. Symptoms may appear 2 to 14 days after exposure to the virus. Symptoms may include: fever or chills; cough; shortness of breath; fatigue; muscle and body aches; headache; new loss of taste or smell; sore throat; congestion or runny nose; nausea or vomiting; diarrhea.

---

<sup>7</sup> A booster dose of SPIKEVAX (COVID-19 Vaccine, mRNA) is 0.25 mL.

<sup>8</sup> A booster dose of the Moderna COVID-19 Vaccine supplied in multiple-dose vials with dark blue caps and labels with a purple border is 0.5 mL.

## DOSAGE AND ADMINISTRATION

### Storage and Handling

The information in this Fact Sheet supersedes the information on the vial and carton labels.

During storage, minimize exposure to room light, and avoid exposure to direct sunlight and ultraviolet light.

### Frozen Storage

Store frozen between -50°C to -15°C (-58°F to 5°F).

### Storage after Thawing

- Storage at 2°C to 8°C (36°F to 46°F):
  - Vials may be stored refrigerated between 2°C to 8°C (36°F to 46°F) for up to 30 days prior to first use.
  - Vials should be discarded 12 hours after the first puncture.
- Storage at 8°C to 25°C (46°F to 77°F):
  - Vials may be stored between 8°C to 25°C (46°F to 77°F) for a total of 24 hours.
  - Vials should be discarded 12 hours after the first puncture.
  - Total storage at 8°C to 25°C (46°F to 77°F) must not exceed 24 hours.

### **Do not refreeze once thawed.**

Thawed vials can be handled in room light conditions.

### Transportation of Thawed Vials at 2°C to 8°C (36°F to 46°F)

If transport at -50°C to -15°C (-58°F to 5°F) is not feasible, available data support transportation of one or more thawed vials for up to 12 hours at 2°C to 8°C (36°F to 46°F) when shipped using shipping containers which have been qualified to maintain 2°C to 8°C (36°F to 46°F) and under routine road and air transport conditions with shaking and vibration minimized. Once thawed and transported at 2°C to 8°C (36°F to 46°F), vials should not be refrozen and should be stored at 2°C to 8°C (36°F to 46°F) until use.

## Dosing and Schedule

### Primary Series<sup>9</sup>

Each primary series dose of the Moderna COVID-19 Vaccine for individuals 12 years of age and older is 0.5 mL.

The Moderna COVID-19 Vaccine supplied in a multiple-dose vial with a red cap and a label with a light blue border is administered as a primary series of two doses (0.5 mL each) 1 month apart to individuals 12 years of age or older.

A third primary series dose (0.5 mL) of the Moderna COVID-19 Vaccine supplied in a multiple-

---

<sup>9</sup> A primary series dose of SPIKEVAX (COVID-19 Vaccine, mRNA) is 0.5 mL.

dose vial with a red cap and a label with a light blue border is authorized for administration at least 1 month following the second dose to individuals at least 12 years of age with certain kinds of immunocompromise.

### Booster Doses<sup>10,11</sup>

#### *First Booster Dose*

A first booster dose (0.25 mL) of the Moderna COVID-19 Vaccine supplied in a multiple-dose vial with a red cap and a label with a light blue border may be administered at least 5 months after completing a primary series of the Moderna COVID-19 Vaccine or SPIKEVAX (COVID-19 Vaccine, mRNA) to individuals 18 years of age or older.

A first booster dose (0.25 mL) of the Moderna COVID-19 Vaccine supplied in a multiple-dose vial with a red cap and a label with a light blue border may be administered to individuals 18 years of age and older as a heterologous booster dose following completion of primary vaccination with another authorized or approved COVID-19 vaccine. The dosing interval for the heterologous booster dose is the same as that authorized for a booster dose of the vaccine used for primary vaccination.

#### *Second Booster Dose*

A second booster dose (0.25 mL) of the Moderna COVID-19 Vaccine supplied in a multiple-dose vial with a red cap and a label with a light blue border may be administered to individuals 50 years of age and older at least 4 months after receipt of a first booster dose of any authorized or approved COVID-19 vaccine.

A second booster dose (0.25 mL) of the Moderna COVID-19 Vaccine supplied in a multiple-dose vial with a red cap and a label with a light blue border may be administered at least 4 months after receipt of a first booster dose of any authorized or approved COVID-19 vaccine to individuals 18 years of age and older with certain kinds of immunocompromise.

### **Preparation for Administration**

- The Moderna COVID-19 Vaccine multiple-dose vial with a red cap and a label with a light blue border is supplied in two volumes:
  - multiple-dose vial containing 5.5 mL
  - multiple-dose vial containing 7.5 mL
- The Moderna COVID-19 Vaccine multiple-dose vial with a red cap and a label with a light blue border contains a frozen suspension that does not contain a preservative and must be thawed prior to administration.
- Verify that the vial of Moderna COVID-19 Vaccine has a red cap and a label with light blue border.
- Thaw each vial before use following the instructions below.

---

<sup>10</sup> A booster dose of SPIKEVAX (COVID-19 Vaccine, mRNA) is 0.25 mL.

<sup>11</sup> A booster dose of the Moderna COVID-19 Vaccine supplied in multiple-dose vials with dark blue caps and labels with a purple border is 0.5 mL.

**Thawing Instructions for Moderna COVID-19 Vaccine Multiple-Dose Vials with Red Caps and Labels with a Light Blue Border**

<b>Multiple-Dose Vial Containing</b>	<b>Thaw in Refrigerator</b>	<b>Thaw at Room Temperature</b>
<b>5.5 mL</b>	Thaw between 2°C to 8°C (36°F to 46°F) for 2 hours and 30 minutes. Let each vial stand at room temperature for 15 minutes before administering.	Alternatively, thaw between 15°C to 25°C (59°F to 77°F) for 1 hour.
<b>7.5 mL</b>	Thaw between 2°C to 8°C (36°F to 46°F) for 3 hours. Let each vial stand at room temperature for 15 minutes before administering.	Alternatively, thaw between 15°C to 25°C (59°F to 77°F) for 1 hour and 30 minutes.

- After thawing, do not refreeze.
- Swirl vial gently after thawing and between each withdrawal. **Do not shake.** Do not dilute the vaccine.
- Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
- The Moderna COVID-19 Vaccine is a white to off-white suspension. It may contain white or translucent product-related particulates. Do not administer if vaccine is discolored or contains other particulate matter.
- Primary series doses of 0.5 mL and booster doses of 0.25 mL may be extracted from vials with red caps and labels with a light blue border, preferentially using low dead-volume syringes and/or needles.
- When extracting only primary series doses, depending on the syringes and needles used, a maximum of 11 doses (range: 10-11 doses) may be extracted from the vial containing 5.5 mL or a maximum of 15 doses (range: 13-15 doses) may be extracted from the vial containing 7.5 mL.
- When extracting only booster doses or a combination of primary series and booster doses, the maximum number of doses that may be extracted from vials with red caps and labels with a light blue border should not exceed 20 doses. Do not puncture the vial stopper more than 20 times.
- If the amount of vaccine remaining in the vial cannot provide a primary series dose (0.5 mL) or booster dose (0.25 mL), discard the vial and contents. Do not pool excess vaccine from multiple vials.
- After the first dose has been withdrawn, the vial should be held between 2°C to 25°C (36°F to 77°F). Record the date and time of first use on the Moderna COVID-19 Vaccine vial label. Discard vial after 12 hours. Do not refreeze.

**Administration**

Administer the Moderna COVID-19 Vaccine intramuscularly.



## **CONTRAINDICATION**

Do not administer the Moderna COVID-19 Vaccine to individuals with a known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Moderna COVID-19 Vaccine (*see Full EUA Prescribing Information*).

## **WARNINGS**

### **Management of Acute Allergic Reactions**

Appropriate medical treatment to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of the Moderna COVID-19 Vaccine.

Monitor Moderna COVID-19 Vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention (CDC) guidelines (<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html>).

### **Myocarditis and Pericarditis**

Postmarketing data demonstrate increased risks of myocarditis and pericarditis, particularly within 7 days following the second dose. The observed risk is highest in males 18 through 24 years of age. Although some cases required intensive care support, available data from short-term follow-up suggest that most individuals have had resolution of symptoms with conservative management. Information is not yet available about potential long-term sequelae.

Some, but not all, observational analyses of postmarketing data suggest that there may be an increased risk of myocarditis and pericarditis in males under 40 years of age following the second dose of the Moderna COVID-19 Vaccine relative to other authorized or approved mRNA COVID-19 vaccines. Although postmarketing data following a booster dose of mRNA vaccines are limited, available evidence suggests a lower myocarditis risk following a booster dose relative to the risk following the primary series second dose.

The CDC has published considerations related to myocarditis and pericarditis after vaccination, including for vaccination of individuals with a history of myocarditis or pericarditis (<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html>).

### **Syncope**

Syncope (fainting) may occur in association with administration of injectable vaccines. Procedures should be in place to avoid injury from fainting.

### **Altered Immunocompetence**

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Moderna COVID-19 Vaccine.

### **Limitations of Vaccine Effectiveness**

The Moderna COVID-19 Vaccine may not protect all vaccine recipients.



## ADVERSE REACTIONS

### *Adverse Reactions in Clinical Trials*

Adverse reactions reported in clinical trials following administration of the Moderna COVID-19 Vaccine include pain at the injection site, fatigue, headache, myalgia, arthralgia, chills, nausea/vomiting, axillary swelling/tenderness, fever, swelling at the injection site, erythema at the injection site, and rash. (See Full EUA Prescribing Information)

### *Adverse Reactions in Post-Authorization Experience*

Anaphylaxis and other severe allergic reactions, myocarditis, pericarditis, and syncope have been reported following administration of the Moderna COVID-19 Vaccine outside of clinical trials.

Additional adverse reactions, some of which may be serious, may become apparent with more widespread use of the Moderna COVID-19 Vaccine.

## USE WITH OTHER VACCINES

There is no information on the co-administration of the Moderna COVID-19 Vaccine with other vaccines.

## INFORMATION TO PROVIDE TO VACCINE RECIPIENTS/CAREGIVERS

As the vaccination provider, you must communicate to the recipient or their caregiver, information consistent with the “Vaccine Information Fact Sheet for Recipients and Caregivers” (and provide a copy or direct the individual to the website [www.modernatx.com/covid19vaccine-eua](http://www.modernatx.com/covid19vaccine-eua) to obtain the Fact Sheet) prior to the individual receiving each dose of the Moderna COVID-19 Vaccine, including:

- FDA has authorized the emergency use of the Moderna COVID-19 Vaccine, which is not an FDA-approved vaccine.
- The recipient or their caregiver has the option to accept or refuse the Moderna COVID-19 Vaccine.
- The significant known and potential risks and benefits of the Moderna COVID-19 Vaccine, and the extent to which such risks and benefits are unknown.
- Information about available alternative vaccines and the risks and benefits of those alternatives.

For information on clinical trials that are evaluating the use of the Moderna COVID-19 Vaccine to prevent COVID-19, please see [www.clinicaltrials.gov](http://www.clinicaltrials.gov).

Provide a vaccination card to the recipient or their caregiver with the date when the recipient needs to return for the second dose of Moderna COVID-19 Vaccine.

Provide the **v-safe** information sheet to vaccine recipients/caregivers and encourage vaccine recipients to participate in **v-safe**. **V-safe** is a voluntary smartphone-based tool that uses text messaging and web surveys to check in with people who have been vaccinated to identify potential side effects after COVID-19 vaccination. **V-safe** asks questions that help CDC monitor the safety of COVID-19 vaccines. **V-safe** also provides second-dose reminders if needed and live telephone follow-up by CDC if participants report a significant health impact following COVID-

19 vaccination. For more information, visit: [www.cdc.gov/vsafe](http://www.cdc.gov/vsafe).

## **MANDATORY REQUIREMENTS FOR MODERNA COVID-19 VACCINE ADMINISTRATION UNDER EMERGENCY USE AUTHORIZATION<sup>12</sup>**

In order to mitigate the risks of using this unapproved product under EUA and to optimize the potential benefit of the Moderna COVID-19 Vaccine, the following items are required. Use of unapproved Moderna COVID-19 Vaccine for active immunization to prevent COVID-19 under this EUA is limited to the following (all requirements **must** be met):

1. The Moderna COVID-19 Vaccine is authorized for use in individuals 6 months of age and older.
2. The vaccination provider must communicate to the individual receiving the Moderna COVID-19 Vaccine or their caregiver information consistent with the “Vaccine Information Fact Sheet for Recipients and Caregivers” prior to the individual receiving the Moderna COVID-19 Vaccine.
3. The vaccination provider must include vaccination information in the state/local jurisdiction’s Immunization Information System (IIS) or other designated system.
4. The vaccination provider is responsible for mandatory reporting of the following to the Vaccine Adverse Event Reporting System (VAERS):
  - vaccine administration errors whether or not associated with an adverse event,
  - serious adverse events\* (irrespective of attribution to vaccination),
  - cases of Multisystem Inflammatory Syndrome (MIS) in adults and children, and
  - cases of COVID-19 that result in hospitalization or death.

Complete and submit reports to VAERS online at <https://vaers.hhs.gov/reportevent.html>. For further assistance with reporting to VAERS, call 1-800-822-7967. The reports should include the words “Moderna COVID-19 Vaccine EUA” in the description section of the report.

5. The vaccination provider is responsible for responding to FDA requests for information about vaccine administration errors, adverse events, cases of MIS in adults and children, and cases of COVID-19 that result in hospitalization or death following administration of the Moderna COVID-19 Vaccine to recipients.

\*Serious adverse events are defined as:

- Death;
- A life-threatening adverse event;
- Inpatient hospitalization or prolongation of existing hospitalization;
- A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions;

---

<sup>12</sup> Vaccination providers administering SPIKEVAX (COVID-19 Vaccine, mRNA) must adhere to the same reporting requirements.

- A congenital anomaly/birth defect;
- An important medical event that based on appropriate medical judgement may jeopardize the individual and may require medical or surgical intervention to prevent one of the outcomes listed above.

#### **OTHER ADVERSE EVENT REPORTING TO VAERS AND MODERNATX, INC.**

Vaccination providers may report to VAERS other adverse events that are not required to be reported using the contact information above.


To the extent feasible, report adverse events to ModernaTX, Inc. using the contact information below or by providing a copy of the VAERS form to ModernaTX, Inc.

Email	Fax number	Telephone number
<a href="mailto:ModernaPV@modernatx.com">ModernaPV@modernatx.com</a>	1-866-599-1342	1-866-MODERNA (1-866-663-3762)

#### **ADDITIONAL INFORMATION**

For general questions, visit the website or call the telephone number provided below.

To access the most recent Moderna COVID-19 Vaccine Fact Sheets, please scan the QR code or visit the website provided below.

Website	Telephone number
<a href="http://www.modernatx.com/covid19vaccine-eua">www.modernatx.com/covid19vaccine-eua</a> 	1-866-MODERNA (1-866-663-3762)

#### **AVAILABLE ALTERNATIVES**

SPIKEVAX (COVID-19 Vaccine, mRNA) and COMIRNATY (COVID-19 Vaccine, mRNA) are FDA-approved vaccines to prevent COVID-19 caused by SARS-CoV-2. There may be clinical trials or availability under EUA of other COVID-19 vaccines.

#### **FEDERAL COVID-19 VACCINATION PROGRAM**

This vaccine is being made available for emergency use exclusively through the CDC COVID-19 Vaccination Program (the Vaccination Program). Healthcare providers must enroll as providers in the Vaccination Program and comply with the provider requirements. Vaccination providers may not charge any fee for the vaccine and may not charge the vaccine recipient any out-of-pocket charge for administration. However, vaccination providers may seek appropriate reimbursement from a program or plan that covers COVID-19 vaccine administration fees for the vaccine recipient (private insurance, Medicare, Medicaid, HRSA COVID-19 Uninsured Program for non-insured recipients). For information regarding provider requirements and

enrollment in the CDC COVID-19 Vaccination Program, see <https://www.cdc.gov/vaccines/covid-19/provider-enrollment.html>.

Individuals becoming aware of any potential violations of the CDC COVID-19 Vaccination Program requirements are encouraged to report them to the Office of the Inspector General, U.S. Department of Health and Human Services, at 1-800-HHS-TIPS or TIPS.HHS.GOV.

#### **AUTHORITY FOR ISSUANCE OF THE EUA**

The Secretary of the Department of Health and Human Services (HHS) has declared a public health emergency that justifies the emergency use of drugs and biological products during the COVID-19 Pandemic. In response, the FDA has issued an EUA for the unapproved product, Moderna COVID-19 Vaccine, and for certain uses of FDA-approved SPIKEVAX (COVID-19 Vaccine, mRNA) for active immunization to prevent COVID-19.

FDA issued this EUA, based on ModernaTX, Inc.'s request and submitted data.

For the authorized uses, although limited scientific information is available, based on the totality of the scientific evidence available to date, it is reasonable to believe that the Moderna COVID-19 Vaccine and SPIKEVAX (COVID-19 Vaccine, mRNA) may be effective for the prevention of COVID-19 in individuals as specified in the *Full EUA Prescribing Information*.

This EUA for the Moderna COVID-19 Vaccine and SPIKEVAX (COVID-19 Vaccine, mRNA) will end when the Secretary of HHS determines that the circumstances justifying the EUA no longer exist or when there is a change in the approval status of the product such that an EUA is no longer needed.

For additional information about Emergency Use Authorization, visit FDA at: <https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization>.

#### **COUNTERMEASURES INJURY COMPENSATION PROGRAM**

The Countermeasures Injury Compensation Program (CICP) is a federal program that has been created to help pay for related costs of medical care and other specific expenses to compensate people injured after use of certain medical countermeasures. Medical countermeasures are specific vaccines, medications, devices, or other items used to prevent, diagnose, or treat the public during a public health emergency or a security threat. For more information about CICP regarding the vaccines to prevent COVID-19, visit <http://www.hrsa.gov/cicp>, email [cicp@hrsa.gov](mailto:cicp@hrsa.gov), or call: 1-855-266-2427.

Moderna US, Inc.  
Cambridge, MA 02139

©2022 ModernaTX, Inc. All rights reserved.

Patent(s): [www.modernatx.com/patents](http://www.modernatx.com/patents)

Revised: June/17/2022

END SHORT VERSION FACT SHEET  
Long Version (Full EUA Prescribing Information) Begins On Next Page

# FULL EMERGENCY USE AUTHORIZATION (EUA) PRESCRIBING INFORMATION

## MODERNA COVID-19 VACCINE

### FULL EUA PRESCRIBING INFORMATION: CONTENTS\*

#### 1 AUTHORIZED USE

#### 2 DOSAGE AND ADMINISTRATION

##### 2.1 Preparation for Administration

##### 2.2 Administration

##### 2.3 Dosing and Schedule

#### 3 DOSAGE FORMS AND STRENGTHS

#### 4 CONTRAINDICATIONS

#### 5 WARNINGS AND PRECAUTIONS

##### 5.1 Management of Acute Allergic Reactions

##### 5.2 Myocarditis and Pericarditis

##### 5.3 Syncope

##### 5.4 Altered Immunocompetence

##### 5.5 Limitations of Vaccine Effectiveness

#### 6 OVERALL SAFETY SUMMARY

##### 6.1 Clinical Trials Experience

##### 6.2 Post-Authorization Experience

#### 8 REQUIREMENTS AND INSTRUCTIONS FOR REPORTING ADVERSE EVENTS AND VACCINE

#### ADMINISTRATION ERRORS

#### 10 DRUG INTERACTIONS

#### 11 USE IN SPECIFIC POPULATIONS

##### 11.1 Pregnancy

##### 11.2 Lactation

##### 11.3 Pediatric Use

##### 11.4 Geriatric Use

##### 11.5 Use in Immunocompromised Individuals

#### 13 DESCRIPTION

#### 14 CLINICAL PHARMACOLOGY

##### 14.1 Mechanism of Action

#### 18 CLINICAL TRIAL RESULTS AND SUPPORTING DATA FOR EUA

##### 18.1 Efficacy of Two-Dose Primary Series in Participants 18 Years and Older

##### 18.2 Effectiveness of Two-Dose Primary Series in Adolescents 12 Years Through 17 Years of Age

##### 18.3 Immunogenicity of a Third Primary Series Dose in Individuals with Certain Kinds of Immunocompromise

##### 18.4 Immunogenicity of a First Booster Dose Following a Moderna COVID-19 Vaccine Primary Series in Participants 18 Years and Older

##### 18.5 Immunogenicity of a First Booster Dose Following Primary Vaccination with Another Authorized or Approved COVID- 19 Vaccine

##### 18.6 Immunogenicity of a Second Booster Dose

#### 19 HOW SUPPLIED/STORAGE AND HANDLING

#### 20 PATIENT COUNSELING INFORMATION

#### 21 CONTACT INFORMATION

\*Sections or subsections omitted from the full prescribing  
information are not listed

---

## FULL EMERGENCY USE AUTHORIZATION (EUA) PRESCRIBING INFORMATION

### 1 AUTHORIZED USE

Moderna COVID-19 Vaccine is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 6 months of age and older.

This EUA Prescribing Information pertains only to Moderna COVID-19 Vaccine supplied in a multiple-dose vial with a red cap and a label with a light blue border which is authorized for use for primary series doses in individuals 12 years of age and older and booster doses in individuals 18 years of age and older.

### 2 DOSAGE AND ADMINISTRATION

For intramuscular injection only.

The storage, preparation, and administration information in this Prescribing Information apply to the Moderna COVID-19 Vaccine, supplied in a multiple-dose vials with red caps and labels with a light blue border, which is authorized for use for primary series doses in individuals 12 years of

age and older and booster doses in individuals 18 years of age and older.

## 2.1 Preparation for Administration

- The Moderna COVID-19 Vaccine multiple-dose vial with a red cap and a label with a light blue border is supplied in two volumes:
  - multiple-dose vial containing 5.5 mL
  - multiple-dose vial containing 7.5 mL
- The Moderna COVID-19 Vaccine multiple-dose vial with a red cap and a label with a light blue border contains a frozen suspension that does not contain a preservative and must be thawed prior to administration.
- Verify that the vial of Moderna COVID-19 Vaccine has a red cap and a label with light blue border.
- Thaw each vial before use following the instructions below.

### Thawing Instructions for Moderna COVID-19 Vaccine Multiple-Dose Vials with Red Caps and Labels with a Light Blue Border

Multiple-Dose Vial Containing	Thaw in Refrigerator	Thaw at Room Temperature
5.5 mL	Thaw between 2°C to 8°C (36°F to 46°F) for 2 hours and 30 minutes. Let each vial stand at room temperature for 15 minutes before administering.	Alternatively, thaw between 15°C to 25°C (59°F to 77°F) for 1 hour.
7.5 mL	Thaw between 2°C to 8°C (36°F to 46°F) for 3 hours. Let each vial stand at room temperature for 15 minutes before administering.	Alternatively, thaw between 15°C to 25°C (59°F to 77°F) for 1 hour and 30 minutes.

- After thawing, do not refreeze.
- Swirl vial gently after thawing and between each withdrawal. **Do not shake.** Do not dilute the vaccine.
- Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
- The Moderna COVID-19 Vaccine is a white to off-white suspension. It may contain white or translucent product-related particulates. Do not administer if vaccine is discolored or contains other particulate matter.
- Primary series doses of 0.5 mL and booster doses of 0.25 mL may be extracted from vials with red caps and labels with a light blue border, preferentially using low dead-volume syringes and/or needles.
- When extracting only primary series doses, depending on the syringes and needles used, a maximum of 11 doses (range: 10-11 doses) may be extracted from the vial containing



5.5 mL or a maximum of 15 doses (range: 13-15 doses) may be extracted from the vial containing 7.5 mL.

- When extracting only booster doses or a combination of primary series and booster doses, the maximum number of doses that may be extracted from vials with red caps and labels with a light blue border should not exceed 20 doses. Do not puncture the vial stopper more than 20 times.
- If the amount of vaccine remaining in the vial cannot provide a primary series dose (0.5 mL) or booster dose (0.25 mL), discard the vial and contents. Do not pool excess vaccine from multiple vials.
- After the first dose has been withdrawn, the vial should be held between 2°C to 25°C (36°F to 77°F). Record the date and time of first use on the Moderna COVID-19 Vaccine vial label. Discard vial after 12 hours. Do not refreeze.

## 2.2 Administration

Administer the Moderna COVID-19 Vaccine intramuscularly.

## 2.3 Dosing and Schedule

### Primary Series<sup>13</sup>

Each primary series dose of the Moderna COVID-19 Vaccine for individuals 12 years of age and older is 0.5 mL.

The Moderna COVID-19 Vaccine supplied in a multiple-dose vial with a red cap and a label with a light blue border is administered as a primary series of two doses (0.5 mL each) 1 month apart to individuals 12 years of age or older.

A third primary series dose (0.5 mL) of the Moderna COVID-19 Vaccine supplied in a multiple-dose vial with a red cap and a label with a light blue border is authorized for administration at least 1 month following the second dose to individuals at least 12 years of age with certain kinds of immunocompromise.<sup>14</sup>

### Booster Doses<sup>15,16</sup>

#### *First Booster Dose*

A first booster dose (0.25 mL) of the Moderna COVID-19 Vaccine supplied in a multiple-dose vial with a red cap and a label with a light blue border may be administered at least 5 months after completing a primary series of the Moderna COVID-19 Vaccine or SPIKEVAX (COVID-19 Vaccine, mRNA) to individuals 18 years of age or older.

---

<sup>13</sup> A primary series dose of SPIKEVAX (COVID-19 Vaccine, mRNA) is 0.5 mL.

<sup>14</sup> Certain kinds of immunocompromise refers to individuals who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.

<sup>15</sup> A booster dose of SPIKEVAX (COVID-19 Vaccine, mRNA) is 0.25 mL.

<sup>16</sup> A booster dose of the Moderna COVID-19 Vaccine supplied in multiple-dose vials with dark blue caps and labels with a purple border is 0.5 mL.

A first booster dose (0.25 mL) of the Moderna COVID-19 Vaccine supplied in a multiple-dose vial with a red cap and a label with a light blue border may be administered to individuals 18 years of age and older as a heterologous booster dose following completion of primary vaccination with another authorized or approved COVID-19 vaccine. The dosing interval for the heterologous booster dose is the same as that authorized for a booster dose of the vaccine used for primary vaccination.

#### *Second Booster Dose*

A second booster dose (0.25 mL) of the Moderna COVID-19 Vaccine supplied in a multiple-dose vial with a red cap and a label with a light blue border may be administered to individuals 50 years of age and older at least 4 months after receipt of a first booster dose of any authorized or approved COVID-19 vaccine.

A second booster dose (0.25 mL) of the Moderna COVID-19 Vaccine supplied in a multiple-dose vial with a red cap and a label with a light blue border may be administered at least 4 months after receipt of a first booster dose of any authorized or approved COVID-19 vaccine to individuals 18 years of age and older with certain kinds of immunocompromise.

### **3 DOSAGE FORMS AND STRENGTHS**

Moderna COVID-19 Vaccine supplied in a multiple-dose vial with a red cap and a label with a light blue border is a suspension for injection.

- Each primary series dose is 0.5 mL.
- The booster dose is 0.25 mL.

### **4 CONTRAINDICATIONS**

Do not administer the Moderna COVID-19 Vaccine to individuals with a known history of severe allergic reaction (e.g., anaphylaxis) to any component of the Moderna COVID-19 Vaccine [*see Description (13)*].

### **5 WARNINGS AND PRECAUTIONS**

#### **5.1 Management of Acute Allergic Reactions**

Appropriate medical treatment to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of the Moderna COVID-19 Vaccine.

Monitor Moderna COVID-19 Vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention (CDC) guidelines (<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html>).

#### **5.2 Myocarditis and Pericarditis**

Postmarketing data demonstrate increased risks of myocarditis and pericarditis, particularly

within 7 days following the second dose. The observed risk is highest in males 18 through 24 years of age. Although some cases required intensive care support, available data from short-term follow-up suggest that most individuals have had resolution of symptoms with conservative management. Information is not yet available about potential long-term sequelae.

Some, but not all, observational analyses of postmarketing data suggest that there may be an increased risk of myocarditis and pericarditis in males under 40 years of age following the second dose of the Moderna COVID-19 Vaccine relative to other authorized or approved mRNA COVID-19 vaccines. Although postmarketing data following a booster dose of mRNA vaccines are limited, available evidence suggests a lower myocarditis risk following a booster dose relative to the risk following the primary series second dose.

The CDC has published considerations related to myocarditis and pericarditis after vaccination, including for vaccination of individuals with a history of myocarditis or pericarditis (<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html>).

### 5.3 Syncope

Syncope (fainting) may occur in association with administration of injectable vaccines. Procedures should be in place to avoid injury from fainting.

### 5.4 Altered Immunocompetence

Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished response to the Moderna COVID-19 Vaccine.

### 5.5 Limitations of Vaccine Effectiveness

The Moderna COVID-19 Vaccine may not protect all vaccine recipients.

## 6 OVERALL SAFETY SUMMARY

**It is MANDATORY for vaccination providers to report to the Vaccine Adverse Event Reporting System (VAERS) all vaccine administration errors, all serious adverse events, cases of Multisystem Inflammatory Syndrome (MIS) in adults and children, and hospitalized or fatal cases of COVID-19 following vaccination with the Moderna COVID-19 Vaccine.<sup>17</sup> To the extent feasible, provide a copy of the VAERS form to ModernaTX, Inc. Please see the REQUIREMENTS AND INSTRUCTIONS FOR REPORTING ADVERSE EVENTS AND VACCINE ADMINISTRATION ERRORS section for details on reporting to VAERS and ModernaTX, Inc.**

#### Primary Series

In a clinical study, the adverse reactions in participants 18 years of age and older following

---

<sup>17</sup> Vaccination providers administering SPIKEVAX (COVID-19 Vaccine, mRNA) must adhere to the same reporting requirements.

administration of the primary series included pain at the injection site (92.0%), fatigue (70.0%), headache (64.7%), myalgia (61.5%), arthralgia (46.4%), chills (45.4%), nausea/vomiting (23.0%), axillary swelling/tenderness (19.8%), fever (15.5%), swelling at the injection site (14.7%), and erythema at the injection site (10.0%).

In a clinical study, the adverse reactions in participants 12 years through 17 years of age following administration of the primary series included pain at the injection site (97.2%), headache (78.4%), fatigue (75.2%), myalgia (54.3%), chills (49.1%), arthralgia (34.6%), axillary swelling/tenderness (34.6%), nausea/vomiting (29.3%), swelling at the injection site (27.7%), erythema at the injection site (25.8%), and fever (13.7%).

### Booster Dose

In a clinical study, the adverse reactions in participants 18 years of age and older following administration of a booster dose included pain at the injection site (83.8%), fatigue (58.7%), headache (55.1%), myalgia (49.1%), arthralgia (41.3%), chills (35.3%), axillary swelling/tenderness (20.4%), nausea/vomiting (11.4%), fever (6.6%), swelling at the injection site (5.4%), erythema at the injection site (4.8%), and rash (1.8%).

### Post-Authorization Experience

Anaphylaxis and other severe allergic reactions, myocarditis, pericarditis, and syncope have been reported following administration of the Moderna COVID-19 Vaccine outside of clinical trials.

## **6.1 Clinical Trials Experience**

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared with rates in the clinical trials of another vaccine and may not reflect the rates observed in practice.

Overall, 39,000 participants aged 6 months and older received at least one dose of Moderna COVID-19 Vaccine in five clinical trials (NCT04283461, NCT04405076, NCT04470427, NCT04649151, and NCT04796896). In a sixth clinical trial (NCT04885907), 60 solid organ transplant recipients received a third dose of Moderna COVID-19 Vaccine.

Study 1 (NCT04470427) is a Phase 3 randomized, placebo-controlled, observer-blind clinical trial conducted in the United States involving 30,346 participants 18 years of age and older who received at least one dose of Moderna COVID-19 Vaccine<sup>18</sup> (n=15,184) or placebo (n=15,162). Study 2 (NCT04405076) is a Phase 2, randomized, observer-blind, placebo-controlled, dose-confirmation study, which included an open-label phase involving 171 participants 18 years of age and older who received a booster dose of Moderna COVID-19 Vaccine 6 months (range of 5.8 to 8.5 months) after receiving the second dose of the primary series. Study 3 (NCT04649151) is a Phase 2/3 randomized, placebo-controlled, observer-blind, clinical trial conducted in the United States involving 3,726 participants 12 years through 17 years of age who received at least

---

<sup>18</sup> Moderna COVID-19 Vaccine is marketed as SPIKEVAX (COVID-19 Vaccine, mRNA), which is approved for use in individuals 18 years of age and older.

one dose of Moderna COVID-19 Vaccine (n=2,486) or placebo (n=1,240). Study 4 (NCT04796896) includes an ongoing Phase 2/3 randomized, placebo-controlled, observer-blind clinical trial component conducted in the United States and Canada involving 10,390 participants 6 months through 11 years of age who received at least one dose of Moderna COVID-19 Vaccine (n=7,799) or placebo (n=2,591).

### **Two-Dose Primary Series in Participants 18 Years and Older**

The safety of Moderna COVID-19 Vaccine was evaluated in an ongoing Phase 3 randomized, placebo-controlled, observer-blind clinical trial conducted in the United States involving 30,346 participants 18 years of age and older who received at least one dose of Moderna COVID-19 Vaccine (n=15,184) or placebo (n=15,162) (Study 1, NCT04470427). Upon issuance of the Emergency Use Authorization (December 18, 2020) for Moderna COVID-19 Vaccine, participants were unblinded in a phased manner over a period of months to offer placebo participants Moderna COVID-19 Vaccine. The median duration of follow up for safety after the second injection during the blinded phase was 4 months. The median duration of follow up for safety after the second injection including both the blinded phase and the open-label phase was 6 months.

In Study 1, the median age of the population was 52 years (range 18-95); 22,826 (75.2%) participants were 18 to 64 years of age and 7,520 (24.8%) participants were 65 years of age and older. Overall, 52.6% of the participants were male, 47.4% were female, 20.5% were Hispanic or Latino, 79.2% were White, 10.2% were African American, 4.6% were Asian, 0.8% were American Indian or Alaska Native, 0.2% were Native Hawaiian or Pacific Islander, 2.0% were other races, and 2.1% were Multiracial. Demographic characteristics were similar between participants who received Moderna COVID-19 Vaccine and those who received placebo.

### **Solicited Adverse Reactions**

Local and systemic adverse reactions and use of antipyretic medication were solicited in an electronic diary for 7 days following each injection (i.e., day of vaccination and the next 6 days) among participants receiving Moderna COVID-19 Vaccine (n=15,179) and participants receiving placebo (n=15,159) with at least 1 documented dose. Events that persisted for more than 7 days were followed until resolution. Solicited adverse reactions were reported more frequently among vaccine participants than placebo participants.

The reported number and percentage of the solicited local and systemic adverse reactions by age group and dose are presented in Table 1 and Table 2, respectively.

**Table 1: Number and Percentage of Participants With Solicited Local and Systemic Adverse Reactions Starting Within 7 Days\* After Each Dose in Participants 18 Years Through 64 Years (Solicited Safety Set, Dose 1 and Dose 2)<sup>†</sup>**

	Moderna COVID-19 Vaccine		Placebo <sup>a</sup>	
	Dose 1 (N=11,406) n (%)	Dose 2 (N=11,000) n (%)	Dose 1 (N=11,402) n (%)	Dose 2 (N=10,929) n (%)
<b>Local Adverse Reactions</b>				
Pain	9,908 (86.9)	9,893 (89.9)	2,183 (19.1)	2,048 (18.7)
Pain, Grade 3 <sup>b</sup>	366 (3.2)	506 (4.6)	23 (0.2)	22 (0.2)
Axillary swelling/tenderness	1,322 (11.6)	1,777 (16.2)	567 (5.0)	474 (4.3)
Axillary swelling/tenderness, Grade 3 <sup>b</sup>	37 (0.3)	47 (0.4)	13 (0.1)	12 (0.1)
Swelling (hardness) ≥25 mm	766 (6.7)	1,399 (12.7)	42 (0.4)	46 (0.4)
Swelling (hardness), Grade 3 <sup>c</sup>	62 (0.5)	183 (1.7)	3 (<0.1)	5 (<0.1)
Erythema (redness) ≥25 mm	354 (3.1)	989 (9.0)	54 (0.5)	53 (0.5)
Erythema (redness), Grade 3 <sup>c</sup>	34 (0.3)	210 (1.9)	11 (<0.1)	12 (0.1)
<b>Systemic Adverse Reactions</b>				
Fatigue	4,385 (38.5)	7,453 (67.8)	3,281 (28.8)	2,701 (24.7)
Fatigue, Grade 3 <sup>d</sup>	121 (1.1)	1,178 (10.7)	83 (0.7)	88 (0.8)
Fatigue, Grade 4 <sup>e</sup>	1 (<0.1)	0 (0)	0 (0)	0 (0)
Headache	4,028 (35.3)	6,929 (63.0)	3,303 (29.0)	2,775 (25.4)
Headache, Grade 3 <sup>f</sup>	220 (1.9)	559 (5.1)	163 (1.4)	132 (1.2)
Myalgia	2,700 (23.7)	6,789 (61.7)	1,625 (14.3)	1,425 (13.0)
Myalgia, Grade 3 <sup>d</sup>	74 (0.6)	1,116 (10.1)	38 (0.3)	42 (0.4)
Arthralgia	1,892 (16.6)	5,010 (45.6)	1,327 (11.6)	1,180 (10.8)
Arthralgia, Grade 3 <sup>d</sup>	47 (0.4)	650 (5.9)	30 (0.3)	37 (0.3)
Arthralgia, Grade 4 <sup>e</sup>	1 (<0.1)	0 (0)	0 (0)	0 (0)
Chills	1,050 (9.2)	5,357 (48.7)	730 (6.4)	662 (6.1)
Chills, Grade 3 <sup>g</sup>	17 (0.1)	164 (1.5)	8 (<0.1)	15 (0.1)

	Moderna COVID-19 Vaccine		Placebo <sup>a</sup>	
	Dose 1 (N=11,406) n (%)	Dose 2 (N=11,000) n (%)	Dose 1 (N=11,402) n (%)	Dose 2 (N=10,929) n (%)
Nausea/vomiting	1,068 (9.4)	2,355 (21.4)	908 (8.0)	807 (7.4)
Nausea/vomiting, Grade 3 <sup>h</sup>	6 (<0.1)	11 (0.1)	8 (<0.1)	8 (<0.1)
Fever	102 (0.9)	1,909 (17.4)	37 (0.3)	38 (0.3)
Fever, Grade 3 <sup>i</sup>	10 (<0.1)	185 (1.7)	1 (<0.1)	2 (<0.1)
Fever, Grade 4 <sup>j</sup>	4 (<0.1)	12 (0.1)	4 (<0.1)	2 (<0.1)
Use of antipyretic or pain medication	2,656 (23.3)	6,307 (57.3)	1,523 (13.4)	1,254 (11.5)

\* 7 days included day of vaccination and the subsequent 6 days. Events and use of antipyretic or pain medication were collected in the electronic diary (e-diary).

† Absence of rows for Grade 4 adverse reactions indicates no events were reported.

<sup>a</sup> Placebo was a saline solution.

<sup>b</sup> Grade 3 pain and axillary swelling/tenderness: Defined as any use of prescription pain reliever; prevents daily activity.

<sup>c</sup> Grade 3 swelling and erythema: Defined as >100 mm / >10 cm.

<sup>d</sup> Grade 3 fatigue, myalgia, arthralgia: Defined as significant; prevents daily activity.

<sup>e</sup> Grade 4 fatigue, arthralgia: Defined as requires emergency room visit or hospitalization.

<sup>f</sup> Grade 3 headache: Defined as significant; any use of prescription pain reliever or prevents daily activity.

<sup>g</sup> Grade 3 chills: Defined as prevents daily activity and requires medical intervention.

<sup>h</sup> Grade 3 nausea/vomiting: Defined as prevents daily activity; requires outpatient intravenous hydration.

<sup>i</sup> Grade 3 fever: Defined as  $\geq 39.0^{\circ} - \leq 40.0^{\circ}\text{C}$  /  $\geq 102.1^{\circ} - \leq 104.0^{\circ}\text{F}$ .

<sup>j</sup> Grade 4 fever: Defined as  $> 40.0^{\circ}\text{C}$  /  $> 104.0^{\circ}\text{F}$ .

**Table 2: Number and Percentage of Participants With Solicited Local and Systemic Adverse Reactions Starting Within 7 Days\* After Each Dose in Participants 65 Years and Older (Solicited Safety Set, Dose 1 and Dose 2)<sup>†</sup>**

	Moderna COVID-19 Vaccine		Placebo <sup>a</sup>	
	Dose 1 (N=3,760) n (%)	Dose 2 (N=3,691) n (%)	Dose 1 (N=3,749) n (%)	Dose 2 (N=3,649) n (%)
<b>Local Adverse Reactions</b>				
Pain	2,780 (73.9)	3,071 (83.2)	482 (12.9)	438 (12.0)
Pain, Grade 3 <sup>b</sup>	50 (1.3)	100 (2.7)	32 (0.9)	19 (0.5)
Axillary swelling/tenderness	231 (6.1)	315 (8.5)	155 (4.1)	97 (2.7)
Axillary swelling/tenderness, Grade 3 <sup>b</sup>	12 (0.3)	21 (0.6)	14 (0.4)	8 (0.2)



	Moderna COVID-19 Vaccine		Placebo <sup>a</sup>	
	Dose 1 (N=3,760) n (%)	Dose 2 (N=3,691) n (%)	Dose 1 (N=3,749) n (%)	Dose 2 (N=3,649) n (%)
Swelling (hardness) $\geq 25$ mm	169 (4.5)	408 (11.1)	23 (0.6)	14 (0.4)
Swelling (hardness), Grade 3 <sup>c</sup>	20 (0.5)	72 (2.0)	3 ( $<0.1$ )	7 (0.2)
Erythema (redness) $\geq 25$ mm	91 (2.4)	285 (7.7)	23 (0.6)	15 (0.4)
Erythema (redness), Grade 3 <sup>c</sup>	8 (0.2)	77 (2.1)	2 ( $<0.1$ )	3 ( $<0.1$ )
<b>Systemic Adverse Reactions</b>				
Fatigue	1,251 (33.3)	2,154 (58.4)	852 (22.7)	717 (19.6)
Fatigue, Grade 3 <sup>d</sup>	30 (0.8)	255 (6.9)	22 (0.6)	20 (0.5)
Headache	922 (24.5)	1,708 (46.3)	723 (19.3)	652 (17.9)
Headache, Grade 3 <sup>c</sup>	53 (1.4)	107 (2.9)	34 (0.9)	33 (0.9)
Myalgia	742 (19.7)	1,740 (47.2)	444 (11.9)	399 (10.9)
Myalgia, Grade 3 <sup>d</sup>	17 (0.5)	205 (5.6)	9 (0.2)	10 (0.3)
Arthralgia	618 (16.4)	1,293 (35.1)	457 (12.2)	399 (10.9)
Arthralgia, Grade 3 <sup>d</sup>	13 (0.3)	125 (3.4)	8 (0.2)	7 (0.2)
Chills	201 (5.3)	1,143 (31.0)	148 (4.0)	151 (4.1)
Chills, Grade 3 <sup>f</sup>	7 (0.2)	27 (0.7)	6 (0.2)	2 ( $<0.1$ )
Nausea/vomiting	194 (5.2)	439 (11.9)	167 (4.5)	134 (3.7)
Nausea/vomiting, Grade 3 <sup>g</sup>	4 (0.1)	10 (0.3)	5 (0.1)	3 ( $<0.1$ )
Nausea/vomiting, Grade 4 <sup>h</sup>	0 (0)	1 ( $<0.1$ )	0 (0)	0 (0)
Fever	10 (0.3)	367 (9.9)	7 (0.2)	5 (0.1)
Fever, Grade 3 <sup>i</sup>	1 ( $<0.1$ )	18 (0.5)	1 ( $<0.1$ )	0 (0)
Fever, Grade 4 <sup>j</sup>	0 (0)	1 ( $<0.1$ )	2 ( $<0.1$ )	1 ( $<0.1$ )
Use of antipyretic or pain medication	673 (17.9)	1,548 (41.9)	477 (12.7)	331 (9.1)

\* 7 days included day of vaccination and the subsequent 6 days. Events and use of antipyretic or pain medication were collected in the electronic diary (e-diary).

† Absence of rows for Grade 4 adverse reactions indicates no events were reported.

<sup>a</sup> Placebo was a saline solution.

- <sup>b</sup> Grade 3 pain and axillary swelling/tenderness: Defined as any use of prescription pain reliever; prevents daily activity.
- <sup>c</sup> Grade 3 swelling and erythema: Defined as >100 mm / >10 cm.
- <sup>d</sup> Grade 3 fatigue, myalgia, arthralgia: Defined as significant; prevents daily activity.
- <sup>e</sup> Grade 3 headache: Defined as significant; any use of prescription pain reliever or prevents daily activity.
- <sup>f</sup> Grade 3 chills: Defined as prevents daily activity and requires medical intervention.
- <sup>g</sup> Grade 3 nausea/vomiting: Defined as prevents daily activity; requires outpatient intravenous hydration.
- <sup>h</sup> Grade 4 nausea/vomiting: Defined as requires emergency room visit or hospitalization for hypotensive shock.
- <sup>i</sup> Grade 3 fever: Defined as  $\geq 39.0^{\circ} - \leq 40.0^{\circ}\text{C}$  /  $\geq 102.1^{\circ} - \leq 104.0^{\circ}\text{F}$ .
- <sup>j</sup> Grade 4 fever: Defined as  $>40.0^{\circ}\text{C}$  /  $>104.0^{\circ}\text{F}$ .

Solicited local and systemic adverse reactions reported following administration of Moderna COVID-19 Vaccine had a median duration of 1 to 3 days.

Grade 3 solicited local adverse reactions were more frequently reported after Dose 2 than after Dose 1. Solicited systemic adverse reactions were more frequently reported by vaccine recipients after Dose 2 than after Dose 1.

In Study 1, 2.3% of participants (vaccine=347, placebo=337) had evidence of prior SARS-CoV-2 infection at baseline (immunologic or virologic evidence of prior SARS-CoV-2 infection [defined as positive RT-PCR test and/or positive Elecsys immunoassay result at Day 1]). Overall, among the 347 vaccine participants, there were no notable differences in reactogenicity compared to the 14,750 vaccine participants who had no evidence of prior SARS-CoV-2 infection at baseline (negative RT-PCR test and negative Elecsys immunoassay result at Day 1).

### Unsolicited Adverse Events

Participants were monitored for unsolicited adverse events for 28 days following each dose. Serious adverse events and medically attended adverse events will be recorded for the entire study duration (2 years). Among the 30,346 participants who had received at least 1 dose of vaccine (N=15,184) or placebo (N=15,162), unsolicited adverse events that occurred within 28 days following any vaccination were reported by 31.3% of participants (n=4,752) who received Moderna COVID-19 Vaccine and 28.6% of participants (n=4,338) who received placebo.

During the 28-day follow-up period following any dose, lymphadenopathy-related events were reported by 1.7% of vaccine recipients and 0.8% of placebo recipients. These events included lymphadenopathy, lymphadenitis, lymph node pain, vaccination-site lymphadenopathy, injection-site lymphadenopathy, and axillary mass. This imbalance is consistent with the imbalance observed for solicited axillary swelling/tenderness at the injected arm.

During the 7-day follow-up period of any vaccination, hypersensitivity events of injection site rash or injection site urticaria, likely related to vaccination, were reported by 6 participants in the Moderna COVID-19 Vaccine group and none in the placebo group. Delayed injection site reactions that began >7 days after vaccination were reported in 1.4% of vaccine recipients and 0.7% of placebo recipients. Delayed injection site reactions included pain, erythema, and swelling and are likely related to vaccination.

In the blinded portion of the study, there were 8 reports of facial paralysis (including Bell's

palsy) in the Moderna COVID-19 Vaccine group, and 3 in the placebo group. In the 28-day follow-up period there were two cases of facial paralysis in the Moderna COVID-19 Vaccine group, which occurred on 8 and 22 days, respectively, after vaccination, and one in the placebo group, which occurred 17 days after vaccination. Currently available information on facial paralysis is insufficient to determine a causal relationship with the vaccine.

In the blinded portion of the study, there were 50 reports of herpes zoster in the Moderna COVID-19 Vaccine group, and 23 in the placebo group. In the 28-day period after any vaccination, there were 22 cases of herpes zoster in the Moderna COVID-19 Vaccine group, and 15 in the placebo group. Currently available information on herpes zoster infection is insufficient to determine a causal relationship with the vaccine.

There were no other notable patterns or numerical imbalances between treatment groups for specific categories of adverse events (including other neurologic, neuro-inflammatory, and thrombotic events) that would suggest a causal relationship to Moderna COVID-19 Vaccine.

### Serious Adverse Events

During the blinded phase of the study, serious adverse events were reported by 1.8% (n=268) of participants who received Moderna COVID-19 Vaccine and 1.9% (n=292) of participants who received placebo.

There were three serious adverse events of angioedema/facial swelling in the vaccine group in recipients with a history of injection of dermatological fillers. The onset of swelling was reported 1-2 days after the second dose and was likely related to vaccination.

There were no other notable patterns or imbalances between treatment groups for specific categories of serious adverse events (including neurologic, neuro-inflammatory, and thrombotic events) that would suggest a causal relationship to Moderna COVID-19 Vaccine.

### **Two-Dose Primary Series in Adolescents 12 Years Through 17 Years of Age**

Safety data for Moderna COVID-19 Vaccine in adolescents were collected in an ongoing Phase 2/3 randomized, placebo-controlled, observer-blind, clinical trial conducted in the United States involving 3,726 participants 12 years through 17 years of age who received at least one dose of Moderna COVID-19 Vaccine (n=2,486) or placebo (n=1,240) (Study 3, NCT04649151). Overall, 51.4% were male, 48.6% were female, 11.6% were Hispanic or Latino, 83.9% were White, 3.4% were African American, 5.9% were Asian, 0.5% were American Indian or Alaska Native, <0.1% were Native Hawaiian or Pacific Islander, 1.0% were other races, and 4.5% were Multiracial. Demographic characteristics were similar among participants who received Moderna COVID-19 Vaccine and those who received placebo.

### Solicited Adverse Reactions

Local and systemic adverse reactions and use of antipyretic medication were solicited in an electronic diary for 7 days following each injection (i.e., day of vaccination and the next 6 days)

among participants receiving Moderna COVID-19 Vaccine (n=2,485) and participants receiving placebo (n=1,240) with at least 1 documented dose. Events that persisted for more than 7 days were followed until resolution.

The reported number and percentage of the solicited local and systemic adverse reactions in participants 12 years through 17 years of age by dose are presented in Table 3.

**Table 3: Number and Percentage of Participants With Solicited Local and Systemic Adverse Reactions Starting Within 7 Days\* After Each Dose in Participants 12 Years Through 17 Years (Solicited Safety Set, Dose 1 and Dose 2)<sup>†</sup>**

	Moderna COVID-19 Vaccine		Placebo <sup>a</sup>	
	Dose 1 (N=2,482) n (%)	Dose 2 (N=2,478) n (%)	Dose 1 (N=1,238) n (%)	Dose 2 (N=1,220) n (%)
<b>Local Adverse Reactions</b>				
Pain	2,310 (93.1)	2,290 (92.4)	431 (34.8)	370 (30.3)
Pain, Grade 3 <sup>b</sup>	133 (5.4)	126 (5.1)	1 ( $<0.1$ )	3 (0.2)
Axillary swelling/tenderness	578 (23.3)	519 (21.0)	101 (8.2)	61 (5.0)
Axillary swelling/tenderness, Grade 3 <sup>b</sup>	10 (0.4)	7 (0.3)	0 (0)	0 (0)
Swelling (hardness) $\geq 25$ mm	403 (16.2)	509 (20.5)	12 (1.0)	12 (1.0)
Swelling (hardness), Grade 3 <sup>c</sup>	27 (1.1)	56 (2.3)	0 (0)	0 (0)
Erythema (redness) $\geq 25$ mm	334 (13.5)	484 (19.5)	8 (0.6)	11 (0.9)
Erythema (redness), Grade 3 <sup>c</sup>	21 (0.8)	72 (2.9)	0 (0)	0 (0)
<b>Systemic Adverse Reactions</b>				
Fatigue	1,188 (47.9)	1,679 (67.8)	453 (36.6)	353 (28.9)
Fatigue, Grade 3 <sup>d</sup>	33 (1.3)	188 (7.6)	18 (1.5)	10 (0.8)
Headache	1,106 (44.6)	1,739 (70.2)	477 (38.5)	370 (30.3)
Headache, Grade 3 <sup>e</sup>	56 (2.3)	112 (4.5)	17 (1.4)	14 (1.1)
Headache, Grade 4 <sup>f</sup>	0 (0)	1 ( $<0.1$ )	0 (0)	0 (0)
Myalgia	668 (26.9)	1,154 (46.6)	205 (16.6)	153 (12.5)
Myalgia, Grade 3 <sup>d</sup>	24 (1.0)	129 (5.2)	10 (0.8)	3 (0.2)
Arthralgia	371 (15.0)	716 (28.9)	143 (11.6)	113 (9.3)

	Moderna COVID-19 Vaccine		Placebo <sup>a</sup>	
	Dose 1 (N=2,482) n (%)	Dose 2 (N=2,478) n (%)	Dose 1 (N=1,238) n (%)	Dose 2 (N=1,220) n (%)
Arthralgia, Grade 3 <sup>d</sup>	15 (0.6)	57 (2.3)	5 (0.4)	2 (0.2)
Chills	456 (18.4)	1,066 (43.0)	138 (11.1)	97 (8.0)
Chills, Grade 3 <sup>g</sup>	4 (0.2)	11 (0.4)	1 ( $<0.1$ )	0 (0)
Nausea/vomiting	281 (11.3)	591 (23.9)	110 (8.9)	106 (8.7)
Nausea/vomiting, Grade 3 <sup>h</sup>	2 ( $<0.1$ )	2 ( $<0.1$ )	0 (0)	0 (0)
Nausea/vomiting, Grade 4 <sup>i</sup>	0 (0)	1 ( $<0.1$ )	0 (0)	0 (0)
Fever	63 (2.5)	302 (12.2)	12 (1.0)	12 (1.0)
Fever, Grade 3 <sup>j</sup>	9 (0.4)	46 (1.9)	1 ( $<0.1$ )	1 ( $<0.1$ )
Fever, Grade 4 <sup>k</sup>	0 (0)	1 ( $<0.1$ )	0 (0)	1 ( $<0.1$ )
Use of antipyretic or pain medication	748 (30.1)	1,242 (50.1)	118 (9.5)	108 (8.9)

\* 7 days included day of vaccination and the subsequent 6 days. Events and use of antipyretic or pain medication were collected in the electronic diary (e-diary).

† Absence of rows for Grade 4 adverse reactions indicates no events were reported.

<sup>a</sup> Placebo was a saline solution.

<sup>b</sup> Grade 3 pain and axillary swelling/tenderness: Defined as any use of prescription pain reliever; prevents daily activity.

<sup>c</sup> Grade 3 swelling and erythema: Defined as  $>100$  mm /  $>10$  cm.

<sup>d</sup> Grade 3 fatigue, myalgia, arthralgia: Defined as significant; prevents daily activity.

<sup>e</sup> Grade 3 headache: Defined as significant; any use of prescription pain reliever or prevents daily activity.

<sup>f</sup> Grade 4 headache: Defined as requires emergency room visit or hospitalization.

<sup>g</sup> Grade 3 chills: Defined as prevents daily activity and requires medical intervention.

<sup>h</sup> Grade 3 nausea/vomiting: Defined as prevents daily activity, requires outpatient intravenous hydration.

<sup>i</sup> Grade 4 nausea/vomiting: Defined as requires emergency room visit or hospitalization for hypotensive shock.

<sup>j</sup> Grade 3 fever: Defined as  $\geq 39.0^{\circ} - \leq 40.0^{\circ}\text{C}$  /  $\geq 102.1^{\circ} - \leq 104.0^{\circ}\text{F}$ .

<sup>k</sup> Grade 4 fever: Defined as  $>40.0^{\circ}\text{C}$  /  $>104.0^{\circ}\text{F}$ .

Solicited local and systemic adverse reactions reported following administration of Moderna COVID-19 Vaccine had a median duration of 1 to 3 days.

An assessment of reactogenicity among participants with evidence of prior SARS-CoV-2 infection (immunologic or virologic evidence of prior SARS-CoV-2 infection [defined as positive RT-PCR test and/or positive Elecsys immunoassay result at Day 1]) compared to those with no evidence of infection at baseline (negative RT-PCR test and negative Elecsys immunoassay result at Day 1) was conducted. In ages 12 years through 17 years, 5.8% of participants (vaccine=147, placebo=69) had evidence of prior SARS-CoV-2 infection at baseline. Table 4 presents the number and percentage of the solicited local and systemic adverse reactions in Moderna COVID-19 Vaccine participants starting within 7 days after each dose by

SARS-CoV-2 status.

**Table 4: Number and Percentage of Participants 12 Years Through 17 Years Who Received Vaccine With Solicited Local and Systemic Adverse Reactions Starting Within 7 Days\* After Each Dose by SARS-CoV-2 Status (Solicited Safety Set, Dose 1 and Dose 2)<sup>†</sup>**

	<b>Baseline SARS-CoV-2 Positive</b>		<b>Baseline SARS-CoV-2 Negative</b>	
	<b>Dose 1 (N=147) n (%)</b>	<b>Dose 2 (N=146) n (%)</b>	<b>Dose 1 (N=2,163) n (%)</b>	<b>Dose 2 (N=2,162) n (%)</b>
<b>Local Adverse Reactions</b>				
Pain	128 (87.1)	124 (84.9)	2,023 (93.5)	2,006 (92.8)
Pain, Grade 3 <sup>a</sup>	9 (6.1)	7 (4.8)	113 (5.2)	114 (5.3)
Axillary swelling/tenderness	58 (39.5)	25 (17.1)	487 (22.5)	465 (21.5)
Axillary swelling/tenderness, Grade 3 <sup>a</sup>	1 (0.7)	0 (0)	9 (0.4)	7 (0.3)
Swelling (hardness) ≥25 mm	24 (16.3)	22 (15.1)	360 (16.6)	449 (20.8)
Swelling (hardness), Grade 3 <sup>b</sup>	4 (2.7)	2 (1.4)	21 (1.0)	50 (2.3)
Erythema (redness) ≥25 mm	19 (12.9)	18 (12.3)	308 (14.2)	432 (20.0)
Erythema (redness), Grade 3 <sup>b</sup>	1 (0.7)	3 (2.1)	19 (0.9)	62 (2.9)
<b>Systemic Adverse Reactions</b>				
Fatigue	103 (70.1)	94 (64.4)	1,004 (46.4)	1,470 (68.0)
Fatigue, Grade 3 <sup>c</sup>	4 (2.7)	5 (3.4)	27 (1.2)	173 (8.0)
Headache	103 (70.1)	90 (61.6)	938 (43.4)	1,527 (70.6)
Headache, Grade 3 <sup>d</sup>	11 (7.5)	7 (4.8)	44 (2.0)	96 (4.4)
Headache, Grade 4 <sup>e</sup>	0 (0)	0 (0)	0 (0)	1 ( $<0.1$ )
Myalgia	63 (42.9)	63 (43.2)	557 (25.8)	1,017 (47.1)
Myalgia, Grade 3 <sup>c</sup>	3 (2.0)	2 (1.4)	19 (0.9)	117 (5.4)
Arthralgia	36 (24.5)	39 (26.7)	305 (14.1)	633 (29.3)
Arthralgia, Grade 3 <sup>c</sup>	2 (1.4)	0 (0)	12 (0.6)	52 (2.4)
Chills	72 (49.0)	63 (43.2)	363 (16.8)	934 (43.2)
Chills, Grade 3 <sup>f</sup>	0 (0)	0 (0)	4 (0.2)	10 (0.5)

	Baseline SARS-CoV-2 Positive		Baseline SARS-CoV-2 Negative	
	Dose 1 (N=147) n (%)	Dose 2 (N=146) n (%)	Dose 1 (N=2,163) n (%)	Dose 2 (N=2,162) n (%)
Nausea/vomiting	30 (20.4)	29 (19.9)	237 (11.0)	522 (24.2)
Nausea/vomiting, Grade 3 <sup>g</sup>	0 (0)	0 (0)	2 ( $<0.1$ )	2 ( $<0.1$ )
Nausea/vomiting, Grade 4 <sup>h</sup>	0 (0)	1 (0.7)	0 (0)	0 (0)
Fever	29 (19.7)	20 (13.7)	33 (1.5)	262 (12.1)
Fever, Grade 3 <sup>i</sup>	4 (2.7)	2 (1.4)	4 (0.2)	40 (1.9)
Fever, Grade 4 <sup>j</sup>	0 (0)	0 (0)	0 (0)	1 ( $<0.1$ )

\* 7 days included day of vaccination and the subsequent 6 days. Events were collected in the electronic diary (e-diary).

† Absence of rows for Grade 4 adverse reactions indicates no events were reported.

<sup>a</sup> Grade 3 pain and axillary swelling/tenderness: Defined as any use of prescription pain reliever; prevents daily activity.

<sup>b</sup> Grade 3 swelling and erythema: Defined as  $>100$  mm /  $>10$  cm.

<sup>c</sup> Grade 3 fatigue, myalgia, arthralgia: Defined as significant; prevents daily activity.

<sup>d</sup> Grade 3 headache: Defined as significant; any use of prescription pain reliever or prevents daily activity.

<sup>e</sup> Grade 4 headache: Defined as requires emergency room visit or hospitalization.

<sup>f</sup> Grade 3 chills: Defined as prevents daily activity and requires medical intervention.

<sup>g</sup> Grade 3 nausea/vomiting: Defined as prevents daily activity, requires outpatient intravenous hydration.

<sup>h</sup> Grade 4 nausea/vomiting: Defined as requires emergency room visit or hospitalization for hypotensive shock.

<sup>i</sup> Grade 3 fever: Defined as  $\geq 39.0^{\circ}$  –  $\leq 40.0^{\circ}\text{C}$  /  $\geq 102.1^{\circ}$  –  $\leq 104.0^{\circ}\text{F}$ .

<sup>j</sup> Grade 4 fever: Defined as  $>40.0^{\circ}\text{C}$  /  $>104.0^{\circ}\text{F}$ .

### Unsolicited Adverse Events

Participants were monitored for unsolicited adverse events for up to 28 days following each dose. Serious adverse events and medically attended adverse events will be recorded for the entire study duration. As of May 8, 2021, among participants who had received at least 1 dose of vaccine or placebo (vaccine=2,486, placebo=1,240), unsolicited adverse events that occurred within 28 days following each vaccination were reported by 20.5% of participants (n=510) who received Moderna COVID-19 Vaccine and 15.9% of participants (n=197) who received placebo. In these analyses, 97.3% of study participants had at least 28 days of follow-up after Dose 2.

During the 28-day follow-up period following any dose, lymphadenopathy-related events that were not necessarily captured in the 7-day e-diary were reported by 5.0% of vaccine recipients and 0.5% of placebo recipients. These events included lymphadenopathy, vaccination-site lymphadenopathy and injection-site lymphadenopathy which were plausibly related to vaccination. This imbalance is consistent with the imbalance observed for solicited axillary swelling/tenderness in the injected arm.

During the 28-day follow-up period following any dose, hypersensitivity adverse events were



reported in 1.8% of vaccine recipients and 0.6% of placebo recipients. Hypersensitivity events in the vaccine group included injection site rash and injection site urticaria, which are likely related to vaccination. Delayed injection site reactions that began >7 days after vaccination were reported in 0.9% of vaccine recipients and in no placebo recipients. Delayed injection site reactions included pain, erythema, and swelling and are likely related to vaccination.

There were no other notable patterns or numerical imbalances between treatment groups for specific categories of adverse events that would suggest a causal relationship to Moderna COVID-19 Vaccine.

### Serious Adverse Events

As of May 8, 2021, serious adverse events were reported by 0.2% (n=6) of participants who received Moderna COVID-19 Vaccine and 0.2% (n=2) of participants who received placebo. In these analyses, 97.3% of study participants had at least 28 days of follow-up after Dose 2, and the median follow-up time for all participants was 53 days after Dose 2.

There were no notable patterns or imbalances between treatment groups for specific categories of serious adverse events that would suggest a causal relationship to Moderna COVID-19 Vaccine.

### Additional Safety Analyses

Study 3 participants started to enter an open-label, observational phase after May 10, 2021. A long-term safety analysis was conducted in participants from Study 3 who received Moderna COVID-19 Vaccine (n=2,486) with a cut-off date of January 31, 2022. In these analyses, the median duration of follow-up including both the blinded and open-label phases was 312 days after Dose 2 and 95.6% of study participants have had at least 6 months of follow-up after Dose 2. Through the cut-off date, there were no serious adverse events causally related to the vaccine.

### **Individuals 6 Years Through 11 Years of Age**

Safety data for Moderna COVID-19 Vaccine from Study 4 included data in 4,002 participants 6 years through 11 years of age who received at least one dose of Moderna COVID-19 Vaccine (n=3,007) or placebo (n=995). As of the data cutoff date of November 10, 2021, the median duration of blinded follow-up for safety was 51 days after Dose 2, and 1,284 participants had been followed for at least 2 months after Dose 2 (vaccine=1,006, placebo=218).

Demographic characteristics in Study 4 were similar among participants who received Moderna COVID-19 Vaccine and those who received placebo. Overall, 50.8% were male, 49.2% were female, 18.5% were Hispanic or Latino, 65.6% were White, 10.0% were African American, 9.9% were Asian, 0.4% were American Indian or Alaska Native, <0.1% were Native Hawaiian or Pacific Islander, 2.1% were other races, and 10.6% were Multiracial.

### Unsolicited Adverse Events

Participants were monitored for unsolicited adverse events for up to 28 days following each

dose. Serious adverse events and medically attended adverse events will be recorded for the entire study duration. As of November 10, 2021, among participants who had received at least 1 dose of vaccine or placebo (vaccine=3,007, placebo=995), unsolicited adverse events that occurred within 28 days following each vaccination were reported by 29.6% of participants (n=891) who received Moderna COVID-19 Vaccine and 25.1% of participants (n=250) who received placebo. In these analyses, 98.6% of study participants had at least 28 days of follow-up after Dose 2.

During the 28-day follow-up period following any dose, lymphadenopathy-related events were reported by 1.8% of vaccine recipients and 0.6% of placebo recipients. These events included lymphadenopathy, lymph node pain, injection-site lymphadenopathy, and vaccination-site lymphadenopathy which were plausibly related to vaccination.

During the 28-day follow-up period following any dose, hypersensitivity adverse events were reported in 4.3% of vaccine recipients and 2.1% of placebo recipients. Hypersensitivity events in the vaccine group included injection site rash and injection site urticaria, which are likely related to vaccination. Delayed injection site reactions that began >7 days after vaccination were reported in 2.7% of vaccine recipients and in 0.2% of placebo recipients. Delayed injection site reactions included pain, erythema, and swelling and are likely related to vaccination.

During the 28-day follow-up period following any dose, events of abdominal pain (including abdominal pain, abdominal pain upper, and abdominal pain lower) were reported by 1.1% of vaccine recipients and 0.6% of placebo recipients. Currently available information is insufficient to determine a causal relationship with the vaccine.

There were no other notable patterns or numerical imbalances between treatment groups for specific categories of adverse events that would suggest a causal relationship to Moderna COVID-19 Vaccine.

### Serious Adverse Events

As of November 10, 2021, serious adverse events were reported by 0.2% (n=6) of participants who received Moderna COVID-19 Vaccine and 0.2% (n=2) participants who received placebo. None of the events in the Moderna COVID-19 Vaccine group were considered related to vaccine. In these analyses, 98.6% of study participants had at least 28 days of follow-up after Dose 2, and the median follow-up time for all participants was 51 days after Dose 2.

There were no notable patterns or imbalances between treatment groups for specific categories of serious adverse events that would suggest a causal relationship to Moderna COVID-19 Vaccine.

### Additional Safety Analyses

Participants 6 years through 11 years in Study 4 started to enter an open-label, observational phase after November 1, 2021. A long-term safety analysis was conducted in participants 6 years through 11 years from Study 4 who received Moderna COVID-19 Vaccine (n=3,007) with a cut-off date of February 21, 2022. In these analyses, the median duration of follow-up including both

the blinded and open-label phases was 158 days after Dose 2. Through the cut-off date, there were no serious adverse events causally related to the vaccine.

### **Individuals 6 Months Through 5 Years of Age**

Safety data for Moderna COVID-19 Vaccine from Study 4 included data in 6,388 participants 6 months through 5 years of age who received at least one dose of Moderna COVID-19 Vaccine (n=4,792) or placebo (n=1,596). As of the data cutoff date of February 21, 2022, the median duration of blinded follow-up for safety for participants 6 months through 23 months was 68 days after Dose 2. For participants 2 years to 5 years, the median duration of blinded follow-up for safety was 71 days after Dose 2.

For participants 6 months through 23 months, 51.1% were male, 48.9% were female, 13.2% were Hispanic or Latino, 79.0% were White, 3.1% were African American, 4.9% were Asian, 0.2% were American Indian or Alaska Native, 0.0% were Native Hawaiian or Pacific Islander, 1.5% were other races, and 10.6% were Multiracial. For participants 2 years through 5 years, 50.8% were male, 49.2% were female, 14.2% were Hispanic or Latino, 76.5% were White, 4.5% were African American, 6.0% were Asian, 0.4% were American Indian or Alaska Native, 0.3% were Native Hawaiian or Pacific Islander, 1.5% were other races, and 10.4% were Multiracial. Demographic characteristics were similar among participants who received Moderna COVID-19 Vaccine and those who received placebo.

### **Unsolicited Adverse Events**

Participants were monitored for unsolicited adverse events for up to 28 days following each dose and follow-up is ongoing. Serious adverse events and medically attended adverse events will be recorded for the entire study duration.

As of February 21, 2022, among participants 6 months through 23 months of age who had received at least 1 dose of vaccine or placebo (vaccine=1,761, placebo=589), unsolicited adverse events that occurred within 28 days following each vaccination were reported by 49.3% of participants (n=869) who received Moderna COVID-19 Vaccine and 48.2% of participants (n=284) who received placebo. In these analyses, 83.1% of study participants 6 months through 23 months of age had at least 28 days of follow-up after Dose 2. Among participants 2 years through 5 years of age who had received at least 1 dose of vaccine or placebo (vaccine=3,031, placebo=1,007), unsolicited adverse events that occurred within 28 days following each vaccination were reported by 40.0% of participants (n=1,212) who received Moderna COVID-19 Vaccine and 37.5% of participants (n=378) who received placebo. In these analyses, 89.3% of study participants 2 years through 5 years of age had at least 28 days of follow-up after Dose 2.

During the 28-day follow-up period following any dose, lymphadenopathy-related events were reported by 1.5% of vaccine recipients and 0.2% of placebo recipients who were 6 months through 23 months of age and 0.9% of vaccine recipients and <0.1% of placebo recipients who were 2 years through 5 years of age. These events included lymphadenopathy, injection-site lymphadenopathy, and vaccination-site lymphadenopathy which were plausibly related to vaccination.

During the 28-day follow-up period following any dose, hypersensitivity adverse events were reported in 3.9% of vaccine recipients and 5.3% of placebo recipients who were 6 months through 23 months of age and 3.5% of vaccine recipients and 2.5% of placebo recipients who were 2 years through 5 years of age. Hypersensitivity events in the vaccine group included injection site rash and injection site urticaria, which are likely related to vaccination. Delayed injection site reactions that began >7 days after vaccination were reported in 1.2% of vaccine recipients and no placebo recipients who were 6 months through 23 months of age and 1.4% of vaccine recipients and <0.1% of placebo recipients who were 2 years through 5 years of age. Delayed injection site reactions included pain, erythema, and swelling and are likely related to vaccination.

During the 28-day follow-up period following any dose, events of abdominal pain (including abdominal pain, abdominal pain upper, and abdominal discomfort) were reported by 0.7% of vaccine recipients and 0.4% of placebo recipients who were 2 years through 5 years of age. Currently available information is insufficient to determine a causal relationship with the vaccine.

There were no other notable patterns or numerical imbalances between treatment groups for specific categories of adverse events that would suggest a causal relationship to Moderna COVID-19 Vaccine.

### Serious Adverse Events

As of February 21, 2022, serious adverse events were reported by 0.9% (n=15) of participants who received vaccine and 0.2% (n=1) of participants who received placebo who were 6 months through 23 months of age and 0.3% (n=9) of participants who received Moderna COVID-19 Vaccine and 0.2% (n=2) of participants who received placebo who were 2 years through 5 years of age. In these analyses, 83.1% of study participants 6 months through 23 months of age had at least 28 days of follow-up after Dose 2, and the median follow-up time for all participants was 68 days after Dose 2. In these analyses, 89.3% of study participants 2 years through 5 years of age had at least 28 days of follow-up after Dose 2, and the median follow-up time for all participants was 71 days after Dose 2.

In participants 6 months through 23 months of age who received the vaccine, a 1-year-old female experienced serious adverse events of a Grade 3 fever 6 hours after Dose 1 and a febrile convulsion 1 day after Dose 1. These events were considered related to vaccination. In participants 2 years through 5 years of age who received Moderna COVID-19 Vaccine, none of the events were considered related to vaccine.

### **A Third Primary Series Dose in Individuals with Certain Kinds of Immunocompromise**

From an independent study (NCT04885907), in 60 adult participants who had undergone various solid organ transplant procedures (heart, kidney, kidney-pancreas, liver, lung, pancreas) a median of 3.57 years previously (range 1.99-6.75 years) who received a third vaccine dose (0.5 mL), the adverse event profile was similar to that after the second dose and no Grade 3 or Grade 4 events

were reported.

### **First Booster Dose Following a Primary Series of Moderna COVID-19 Vaccine or SPIKEVAX (COVID-19 Vaccine, mRNA) in Participants 18 Years and Older**

Study 2 is an ongoing Phase 2, randomized, observer-blind, placebo-controlled, dose-confirmation study to evaluate the safety, reactogenicity, and immunogenicity of the Moderna COVID-19 Vaccine in participants 18 years of age and older (NCT04405076). In this study, 198 participants received two doses (0.5 mL 1 month apart) of the Moderna COVID-19 Vaccine primary series. In an open label-phase, 171 of those participants received a single booster dose (0.25 mL) at least 6 months (range of 5.8 to 8.5 months) after receiving the second dose of the primary series. Safety monitoring after the booster dose was the same as that described for Study 1 participants who received the primary series.

Among the 171 booster dose recipients, the median age was 55 years (range 18-87), 39.2% were male and 60.8% were female, 95.9% were White, 5.8% were Hispanic or Latino, 2.9% were Black or African American, 0.6% were Asian, and 0.6% were American Indian or Alaska Native. Following the booster dose, the median follow-up time was 5.7 months (range of 3.1 to 6.4 months).

#### **Solicited Adverse Reactions**

Table 5 presents the frequency and severity of reported solicited local and systemic adverse reactions among Study 2 Moderna COVID-19 Vaccine booster dose recipients 18 to <65 years of age and ≥65 years of age within 7 days of a booster vaccination.

**Table 5: Number and Percentage of Participants 18 Years of Age and Older With Solicited Local and Systemic Adverse Reactions Starting Within 7 Days\* After the Booster Dose or After the Second Dose of Primary Series (Solicited Safety Set)<sup>†</sup>**

	<b>Participants 18 Years Through 64 Years (N=129) n (%)</b>	<b>Participants ≥65 Years (N=38) n (%)</b>
<b>Local Adverse Reactions</b>		
Pain	111 (86.0)	29 (76.3)
Pain, Grade 3 <sup>a</sup>	4 (3.1)	2 (5.3)
Axillary swelling/tenderness	32 (24.8)	2 (5.3)
Axillary swelling/tenderness, Grade 3 <sup>a</sup>	1 (0.8)	0 (0)
Swelling (hardness) ≥25 mm	8 (6.2)	1 (2.6)
Swelling (hardness) ≥25 mm, Grade 3 <sup>b</sup>	0 (0)	1 (2.6)
Erythema (redness) ≥25 mm	7 (5.4)	1 (2.6)
Erythema (redness), Grade 3 <sup>b</sup>	1 (0.8)	0 (0.0)
<b>Systemic Adverse Reactions</b>		
Fatigue	80 (62.0)	18 (47.4)
Fatigue, Grade 3 <sup>c</sup>	4 (3.1)	3 (7.9)
Headache	76 (58.9)	16 (42.1)
Headache, Grade 3 <sup>d</sup>	1 (0.8)	1 (2.6)

	<b>Participants 18 Years Through 64 Years (N=129) n (%)</b>	<b>Participants ≥65 Years (N=38) n (%)</b>
Myalgia	64 (49.6)	18 (47.4)
Myalgia, Grade 3 <sup>c</sup>	4 (3.1)	1 (2.6)
Arthralgia	54 (41.9)	15 (39.5)
Arthralgia, Grade 3 <sup>c</sup>	4 (3.1)	1 (2.6)
Chills	52 (40.3)	7 (18.4)
Nausea/vomiting	16 (12.4)	3 (7.9)
Fever	9 (7.0)	2 (5.4)
Fever, Grade 3 <sup>c</sup>	2 (1.6)	0 (0.0)
Rash	3 (2.3)	0 (0)
Use of antipyretic or pain medication	64 (49.6)	11 (28.9)

\* 7 days included day of vaccination and the subsequent 6 days. Events and use of antipyretic or pain medication were collected in the electronic diary (e-diary).

† Absence of rows for Grade 3 or Grade 4 adverse reactions indicates no events were reported.

<sup>a</sup> Grade 3 pain and axillary swelling/tenderness: Defined as any use of prescription pain reliever; prevents daily activity.

<sup>b</sup> Grade 3 swelling and erythema: Defined as >100 mm / >10 cm.

<sup>c</sup> Grade 3 fatigue, myalgia, arthralgia: Defined as significant; prevents daily activity.

<sup>d</sup> Grade 3 headache: Defined as significant; any use of prescription pain reliever or prevents daily activity.

<sup>e</sup> Grade 3 fever: Defined as  $\geq 39.0^{\circ} - \leq 40.0^{\circ}\text{C}$  /  $\geq 102.1^{\circ} - \leq 104.0^{\circ}\text{F}$ .

In participants who received a booster dose, the median duration of solicited local and systemic adverse reactions was 2 to 3 days.

### Unsolicited Adverse Events

Overall, the 171 participants who received a booster dose had a median follow-up time of 5.7 months after the booster dose to the cut-off date (August 16, 2021). Through the cut-off date, there were no unsolicited adverse events not already captured as solicited local and systemic reactions that were considered causally related to the Moderna COVID-19 Vaccine.

### Serious Adverse Events

Of the 171 participants who received a booster dose of Moderna COVID-19 Vaccine, there were no serious adverse events reported from the booster dose through 28 days after the booster dose. Through the cut-off date of August 16, 2021, there were no serious adverse events following the booster dose considered causally related to the Moderna COVID-19 Vaccine.

### **First Booster Dose Following Primary Vaccination with Another Authorized or Approved COVID-19 Vaccine**

The safety of a Moderna COVID-19 Vaccine booster dose (0.25 mL) in individuals who completed primary vaccination with another authorized or approved COVID-19 vaccine (heterologous booster dose) is inferred from the safety of a Moderna COVID-19 Vaccine (0.25 mL) booster dose administered following completion of a Moderna COVID-19 Vaccine primary

series (homologous booster dose) and from data from an independent Phase 1/2 open-label clinical trial (NCT04889209) conducted in the United States that evaluated a booster dose (0.5 mL) of the Moderna COVID-19 Vaccine. In this study, adults who had completed primary vaccination with a Moderna COVID-19 Vaccine 2-dose series (N=151), a Janssen COVID-19 Vaccine single dose (N=156), or a Pfizer-BioNTech COVID-19 Vaccine 2-dose series (N=151) at least 12 weeks (range 12 to 20 weeks) prior to enrollment and who reported no history of SARS-CoV-2 infection were randomized 1:1:1 to receive a booster dose of one of three vaccines: Moderna COVID-19 Vaccine (0.5 mL), Janssen COVID-19 Vaccine, or Pfizer-BioNTech COVID-19 Vaccine. Adverse events were assessed through 28 days after the booster dose. An overall review of adverse reactions reported following the Moderna COVID-19 Vaccine heterologous booster dose (0.5 mL) did not identify any new safety concerns, as compared with adverse reactions reported following Moderna COVID-19 Vaccine primary series doses or homologous booster dose (0.25 mL).

## **Second Booster Dose**

In an independently conducted study (*Gili Regev-Yochay, Tal Gonen, Mayan Gilboa, et al. 2022 DOI: 10.1056/NEJMc2202542*), the Moderna COVID-19 Vaccine was administered as a second booster dose to 120 participants 18 years of age and older who had received a 2-dose primary series and a first booster dose of Pfizer-BioNTech COVID-19 Vaccine at least 4 months prior. No new safety concerns were reported during up to three weeks of follow-up after the second booster dose.

## **6.2 Post-Authorization Experience**

The following adverse reactions have been identified during post-authorization use of the Moderna COVID-19 Vaccine. Because these reactions are reported voluntarily, it is not always possible to reliably estimate their frequency or establish a causal relationship to vaccine exposure.

Cardiac Disorders: myocarditis, pericarditis  
Immune System Disorders: anaphylaxis  
Nervous System Disorders: syncope

## **8 REQUIREMENTS AND INSTRUCTIONS FOR REPORTING ADVERSE EVENTS AND VACCINE ADMINISTRATION ERRORS<sup>19</sup>**

See Overall Safety Summary (Section 6) for additional information.

The vaccination provider enrolled in the federal COVID-19 Vaccination Program is responsible for the MANDATORY reporting of the listed events following Moderna COVID-19 Vaccine to the Vaccine Adverse Event Reporting System (VAERS)

- Vaccine administration errors whether or not associated with an adverse event
- Serious adverse events\* (irrespective of attribution to vaccination)

---

<sup>19</sup> Vaccination providers administering SPIKEVAX (COVID-19 Vaccine, mRNA) must adhere to the same reporting requirements.



- Cases of Multisystem Inflammatory Syndrome (MIS) in adults and children
- Cases of COVID-19 that results in hospitalization or death

\*Serious Adverse Events are defined as:

- Death;
- A life-threatening adverse event;
- Inpatient hospitalization or prolongation of existing hospitalization;
- A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions;
- A congenital anomaly/birth defect;
- An important medical event that based on appropriate medical judgement may jeopardize the individual and may require medical or surgical intervention to prevent one of the outcomes listed above.

### Instructions for Reporting to VAERS

The vaccination provider enrolled in the federal COVID-19 Vaccination Program should complete and submit a VAERS form to FDA using one of the following methods:

- Complete and submit the report online: <https://vaers.hhs.gov/reportevent.html>, or
- If you are unable to submit this form electronically, you may fax it to VAERS at 1-877-721-0366. If you need additional help submitting a report, you may call the VAERS toll-free information line at 1-800-822-7967 or send an email to [info@vaers.org](mailto:info@vaers.org).

**IMPORTANT: When reporting adverse events or vaccine administration errors to VAERS, please complete the entire form with detailed information. It is important that the information reported to FDA be as detailed and complete as possible. Information to include:**

- Patient demographics (e.g., patient name, date of birth)
- Pertinent medical history
- Pertinent details regarding admission and course of illness
- Concomitant medications
- Timing of adverse event(s) in relationship to administration of Moderna COVID-19 Vaccine
- Pertinent laboratory and virology information
- Outcome of the event and any additional follow-up information if it is available at the time of the VAERS report. Subsequent reporting of follow-up information should be completed if additional details become available.

The following steps are highlighted to provide the necessary information for safety tracking:

1. In Box 17, provide information on Moderna COVID-19 Vaccine and any other vaccines administered on the same day; and in Box 22, provide information on any other vaccines received within one month prior.
2. In Box 18, description of the event:
  - a. Write “Moderna COVID-19 Vaccine EUA” as the first line
  - b. Provide a detailed report of vaccine administration error and/or adverse event. It

is important to provide detailed information regarding the patient and adverse event/medication error for ongoing safety evaluation of this unapproved vaccine. Please see information to include listed above.

3. Contact information:

- a. In Box 13, provide the name and contact information of the prescribing healthcare provider or institutional designee who is responsible for the report.
- b. In Box 14, provide the name and contact information of the best doctor/healthcare professional to contact about the adverse event.
- c. In Box 15, provide the address of the facility where vaccine was given (NOT the healthcare provider's office address).

### Other Reporting Instructions

Vaccination providers may report to VAERS other adverse events that are not required to be reported using the contact information above.

To the extent feasible, report adverse events to ModernaTX, Inc. using the contact information below or by providing a copy of the VAERS form to ModernaTX, Inc.

Email	Fax number	Telephone number
<a href="mailto:ModernaPV@modernatx.com">ModernaPV@modernatx.com</a>	1-866-599-1342	1-866-MODERNA (1-866-663-3762)

## **10 DRUG INTERACTIONS**

There are no data to assess the concomitant administration of the Moderna COVID-19 Vaccine with other vaccines.

## **11 USE IN SPECIFIC POPULATIONS**

### **11.1 Pregnancy**

#### Pregnancy Exposure Registry

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Moderna COVID-19 Vaccine during pregnancy. Women who are vaccinated with Moderna COVID-19 Vaccine during pregnancy are encouraged to enroll in the registry by calling 1-866-MODERNA (1-866-663-3762).

#### Risk Summary

All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Available data on Moderna COVID-19 Vaccine administered to pregnant women are insufficient to inform vaccine-

associated risks in pregnancy.

In a developmental toxicity study, 0.2 mL of a vaccine formulation containing the same quantity of nucleoside-modified messenger ribonucleic acid (mRNA) (100 mcg) and other ingredients included in a single primary series dose of Moderna COVID-19 Vaccine for individuals 12 years of age and older was administered to female rats by the intramuscular route on four occasions: 28 and 14 days prior to mating, and on gestation days 1 and 13. No vaccine-related adverse effects on female fertility, fetal development, or postnatal development were reported in the study.

## **11.2 Lactation**

### **Risk Summary**

Data are not available to assess the effects of Moderna COVID-19 Vaccine on the breastfed infant or on milk production/excretion.

## **11.3 Pediatric Use**

Moderna COVID-19 Vaccine is authorized for use in individuals 6 months through 17 years of age. This authorization is based on safety and effectiveness data in this age group and adults.

Moderna COVID-19 Vaccine is not authorized for use in individuals younger than 6 months of age.

Moderna COVID-19 Vaccine is not authorized to provide booster doses for individuals younger than 18 years of age.

## **11.4 Geriatric Use**

Clinical studies of Moderna COVID-19 Vaccine included participants 65 years of age and older receiving vaccine or placebo, and their data contribute to the overall assessment of safety and efficacy. In an ongoing Phase 3 clinical study (Study 1) of primary series dosing (0.5 mL), 24.8% (n=7,520) of participants were 65 years of age and older and 4.6% (n=1,399) of participants were 75 years of age and older. Vaccine efficacy in participants 65 years of age and older was 86.4% (95% CI 61.4, 95.2) compared to 95.6% (95% CI 90.6, 97.9) in participants 18 to <65 years of age [see *Clinical Trial Results and Supporting Data for EUA (18.1)*]. Overall, there were no notable differences in the safety profiles observed in participants 65 years of age and older and younger participants [see *Overall Safety Summary (6.1)*].

In an ongoing Phase 2 clinical study (Study 2) of a single booster dose (0.25 mL), 22.2% (n=38) of participants were 65 years of age and older. This study did not include sufficient numbers of participants 65 years of age and older to determine whether they respond differently than younger participants. Some local and systemic adverse reactions were reported in a lower proportion of participants 65 years of age and older compared to participants 18 through 64 years of age [see *Overall Safety Summary (6.1)*].

## 11.5 Use in Immunocompromised Individuals

Safety and effectiveness of Moderna COVID-19 Vaccine in individuals 6 months through 17 years of age with immunocompromise have been extrapolated from adult data. In an independent study (*Hall VG, Ferreira VH, Ku T et al. Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients. N Engl J Med 2021 DOI: 10.1056/NEJMc2111462; NCT04885907*), safety and effectiveness of a third 0.5 mL primary series dose of the Moderna COVID-19 Vaccine have been evaluated in adult participants who received solid organ transplants [see Overall Safety Summary (6.1) and Clinical Trial Results and Supporting Data for EUA (18.3)]. The administration of a third primary series vaccine dose appears to be only moderately effective in increasing antibody titers. Patients should be counseled to maintain physical precautions to help prevent COVID-19. In addition, close contacts of immunocompromised persons should be vaccinated, as appropriate for their health status.

## 13 DESCRIPTION

Moderna COVID-19 Vaccine is provided as a white to off-white suspension for intramuscular injection.

Each 0.5 mL dose of Moderna COVID-19 Vaccine supplied in a multiple-dose vial with a red cap and a label with a light blue border contains 100 mcg of nucleoside-modified messenger RNA (mRNA) encoding the pre-fusion stabilized Spike glycoprotein (S) of SARS-CoV-2 virus. Each 0.5 mL dose of the Moderna COVID-19 Vaccine supplied in a multiple-dose vial with a red cap and a label with a light blue border contains the following ingredients: a total lipid content of 1.93 mg (SM-102, polyethylene glycol [PEG] 2000 dimyristoyl glycerol [DMG], cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC]), 0.31 mg tromethamine, 1.18 mg tromethamine hydrochloride, 0.043 mg acetic acid, 0.20 mg sodium acetate trihydrate, and 43.5 mg sucrose. Each 0.25 mL dose of Moderna COVID-19 Vaccine contains half of these ingredients.

Moderna COVID-19 Vaccine does not contain a preservative.

The vial stoppers are not made with natural rubber latex.

## 14 CLINICAL PHARMACOLOGY

### 14.1 Mechanism of Action

The nucleoside-modified mRNA in the Moderna COVID-19 Vaccine is formulated in lipid particles, which enable delivery of the nucleoside-modified mRNA into host cells to allow expression of the SARS-CoV-2 S antigen. The vaccine elicits an immune response to the S antigen, which protects against COVID-19.

## 18 CLINICAL TRIAL RESULTS AND SUPPORTING DATA FOR EUA

### 18.1 Efficacy of Two-Dose Primary Series in Participants 18 Years and Older

Study 1 is an ongoing Phase 3 randomized, placebo-controlled, observer-blind clinical trial to evaluate the efficacy, safety, and immunogenicity of the Moderna COVID-19 Vaccine in participants 18 years of age and older in the United States (NCT04470427). Randomization was stratified by age and health risk: 18 to <65 years of age without comorbidities (not at risk for progression to severe COVID-19), 18 to <65 years of age with comorbidities (at risk for progression to severe COVID-19), and 65 years of age and older with or without comorbidities. Participants who were immunocompromised and those with a known history of SARS-CoV-2 infection were excluded from the study. Participants with no known history of SARS-CoV-2 infection but with positive laboratory results indicative of infection at study entry were included. The study allowed for the inclusion of participants with stable pre-existing medical conditions, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months before enrollment, as well as participants with stable human immunodeficiency virus (HIV) infection. A total of 30,420 participants were randomized equally to receive 2 doses of the Moderna COVID-19 Vaccine or saline placebo 1 month apart. Participants will be followed for efficacy and safety until 24 months after the second dose.

The primary efficacy analysis population (referred to as the Per-Protocol Set) included 28,207 participants who received two doses (0.5 mL at 0 and 1 month) of either Moderna COVID-19 Vaccine (n=14,134) or placebo (n=14,073) and had a negative baseline SARS-CoV-2 status. In the Per-Protocol Set, 47.4% were female, 19.7% were Hispanic or Latino; 79.5% were White, 9.7% were African American, 4.6% were Asian, and 2.1% other races. The median age of participants was 53 years (range 18-95) and 25.3% of participants were 65 years of age and older. Of the study participants in the Per-Protocol Set, 18.5% were at increased risk of severe COVID-19 due to at least one pre-existing medical condition (chronic lung disease, significant cardiac disease, severe obesity, diabetes, liver disease, or HIV infection) regardless of age. Between participants who received Moderna COVID-19 Vaccine and those who received placebo, there were no notable differences in demographics or pre-existing medical conditions.

#### Efficacy Against COVID-19

COVID-19 was defined based on the following criteria: The participant must have experienced at least two of the following systemic symptoms: fever ( $\geq 38^{\circ}\text{C}$  /  $\geq 100.4^{\circ}\text{F}$ ), chills, myalgia, headache, sore throat, new olfactory and taste disorder(s); or the participant must have experienced at least one of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing, or clinical or radiographical evidence of pneumonia; and the participant must have at least one NP swab, nasal swab, or saliva sample (or respiratory sample, if hospitalized) positive for SARS-CoV-2 by RT-PCR. COVID-19 cases were adjudicated by a Clinical Adjudication Committee.

The median length of follow-up for efficacy for participants in the study was 9 weeks post Dose 2. There were 11 COVID-19 cases in the Moderna COVID-19 Vaccine group and 185 cases in the placebo group, with a vaccine efficacy of 94.1% (95% confidence interval of 89.3% to

96.8%).

**Table 6: Primary Efficacy Analysis: COVID-19\* in Participants 18 Years of Age and Older Starting 14 Days After Dose 2 per Adjudication Committee Assessments – Per-Protocol Set**

Moderna COVID-19 Vaccine			Placebo			% Vaccine Efficacy (95% CI)†
Participants (N)	COVID-19 Cases (n)	Incidence Rate of COVID-19 per 1,000 Person-Years	Participants (N)	COVID-19 Cases (n)	Incidence Rate of COVID-19 per 1,000 Person-Years	
14,134	11	3.328	14,073	185	56.510	94.1 (89.3, 96.8)

\* COVID-19: symptomatic COVID-19 requiring positive RT-PCR result and at least two systemic symptoms or one respiratory symptom. Cases starting 14 days after Dose 2.

† VE and 95% CI from the stratified Cox proportional hazard model.

The subgroup analyses of vaccine efficacy are presented in Table 7.

**Table 7: Subgroup Analyses of Vaccine Efficacy: COVID-19\* Cases Starting 14 Days After Dose 2 per Adjudication Committee Assessments – Per-Protocol Set**

Age Subgroup (Years)	Moderna COVID-19 Vaccine			Placebo			% Vaccine Efficacy (95% CI)†
	Participants (N)	COVID-19 Cases (n)	Incidence Rate of COVID-19 per 1,000 Person-Years	Participants (N)	COVID-19 Cases (n)	Incidence Rate of COVID-19 per 1,000 Person-Years	
18 to <65	10,551	7	2.875	10,521	156	64.625	95.6 (90.6, 97.9)
≥65	3,583	4	4.595	3,552	29	33.728	86.4 (61.4, 95.2)

\* COVID-19: symptomatic COVID-19 requiring positive RT-PCR result and at least two systemic symptoms or one respiratory symptom. Cases starting 14 days after Dose 2.

† VE and 95% CI from the stratified Cox proportional hazard model.

Severe COVID-19 was defined based on confirmed COVID-19 as per the primary efficacy endpoint case definition, plus any of the following: Clinical signs indicative of severe systemic illness, respiratory rate  $\geq 30$  per minute, heart rate  $\geq 125$  beats per minute, SpO2  $\leq 93\%$  on room air at sea level or PaO2/FIO2  $< 300$  mm Hg; or respiratory failure or ARDS (defined as needing high-flow oxygen, non-invasive or mechanical ventilation, or ECMO), evidence of shock (systolic blood pressure  $< 90$  mmHg, diastolic BP  $< 60$  mmHg or requiring vasopressors); or significant acute renal, hepatic, or neurologic dysfunction; or admission to an intensive care unit or death.

Among all participants in the Per-Protocol Set analysis, which included COVID-19 cases confirmed by an adjudication committee, no cases of severe COVID-19 were reported in the Moderna COVID-19 Vaccine group compared with 30 cases reported in the placebo group (incidence rate 9.138 per 1,000 person-years). One PCR-positive case of severe COVID-19 in a vaccine recipient was awaiting adjudication at the time of the analysis.

## 18.2 Effectiveness of Two-Dose Primary Series in Adolescents 12 Years Through 17 Years of Age

Study 3 is an ongoing Phase 2/3 randomized, placebo-controlled, observer-blind, clinical trial to evaluate the safety, reactogenicity, and effectiveness of the Moderna COVID-19 Vaccine in adolescents ages 12 years through 17 years in the United States (NCT04649151). Participants with a known history of SARS-CoV-2 infection were excluded from the study. A total of 3,732 participants were randomized 2:1 to receive 2 doses of the Moderna COVID-19 Vaccine or saline placebo 1 month apart. Participants will be followed for effectiveness and safety until 1 year after the last dose.

Effectiveness in individuals 12 years through 17 years of age is based on a comparison of immune responses in this age group to adults 18 years through 25 years of age.

In Study 3, an analysis was conducted of SARS-CoV-2 50% neutralizing titers and seroresponse rates 28 days after Dose 2 in a subset of adolescents 12 years through 17 years of age in Study 3 and participants 18 years through 25 years of age in Study 1 who had no immunologic or virologic evidence of prior SARS-CoV-2 at baseline. Noninferior immune responses as assessed by geometric mean 50% neutralizing titers and seroresponse rates were demonstrated in a comparison of adolescents 12 years through 17 years of age to participants 18 years through 25 years of age (Table 8).

**Table 8: Summary of Geometric Mean Titer Ratio and Seroresponse Rate – Comparison of Adolescents 12 Years Through 17 Years of Age to Participants 18 Years Through 25 Years of Age – Per-Protocol Immunogenicity Subset**

		Moderna COVID-19 Vaccine			
		12 Years Through 17 Years n=340	18 Years Through 25 Years n=296	12 Years Through 17 Years/ 18 Years Through 25 Years	
Assay	Time Point	GMT (95% CI)*	GMT (95% CI)*	GMT Ratio (95% CI) <sup>a</sup>	Met Noninferiority Objective (Y/N) <sup>b</sup>
SARS-CoV-2 neutralization assay – ID50 (titer) <sup>c</sup>	28 days after Dose 2	1401.7 (1276.3, 1539.4)	1301.3 (1177.0, 1438.8)	1.1 (0.9, 1.2)	Y
		Seroresponse % (95% CI) <sup>d</sup>	Seroresponse % (95% CI) <sup>d</sup>	Difference in Seroresponse Rate % (95% CI) <sup>e</sup>	
		98.8 (97.0, 99.7)	98.6 (96.6, 99.6)	0.2 (-1.8, 2.4)	

GMT = Geometric mean titers

n = Number of subjects with non-missing data at the corresponding timepoint

\* Antibody values reported as below the lower limit of quantification (LLOQ) are replaced by 0.5 x LLOQ. Values greater than the upper limit of quantification (ULOQ) are replaced by the ULOQ if actual values are not available.

<sup>a</sup> The log-transformed antibody levels are analyzed using an analysis of covariance (ANCOVA) model with the group variable (adolescents in Study 3 and young adults in Study 1) as fixed effect. The resulted LS means, difference of LS means, and 95% CI are back transformed to the original scale for presentation.

<sup>b</sup> Noninferiority is declared if the lower bound of the 2-sided 95% CI for the GMR is greater than 0.67, with a point estimate of >0.8 and the lower bound of the 2-sided 95% CI for difference in seroresponse rate is greater than -10%, with a point estimate of >-5%.

<sup>c</sup> SARS-CoV-2 50% inhibitory dose (ID50) neutralization titers were determined using a SARS-CoV-2 Spike-Pseudotyped Virus Neutralization Assay. Quantification of SARS-CoV-2 neutralizing antibodies utilizes lentivirus particles expressing SARS-CoV-2 Spike protein on their surface and contains a firefly luciferase (Luc) reporter gene for quantitative measurements of infection by relative luminescence units (RLU). Neutralization is measured as the serum dilution at which RLU is reduced by 50% (ID50) relative to mean RLU in virus control wells virus but after subtraction of mean RLU in cell control wells.

<sup>d</sup> Seroresponse due to vaccination specific to pseudovirus neutralizing antibody ID50 titer at a subject level is defined in protocol as a change from below LLOQ to equal or above LLOQ, or at least a 3.3-fold rise if baseline is equal to or above LLOQ. An analysis done using seroresponse definition of at least 4-fold rise from baseline, where baseline titers <LLOQ are set to LLOQ for the analysis, showed the same results. 95% CI is calculated using the Clopper-Pearson method.

<sup>e</sup> Difference in seroresponse rate 95% CI is calculated using the Miettinen-Nurminen (score) confidence limits.

A descriptive efficacy analysis evaluating confirmed COVID-19 cases accrued up to the data cutoff date of May 8, 2021, was performed in 3,181 participants who received two doses (at 0 and 1 month) of either Moderna COVID-19 Vaccine (n=2,139) or placebo (n=1,042) and had a negative baseline SARS-CoV-2 status (referred to as the Per-Protocol Set for Efficacy). In the Per-Protocol Set for Efficacy, 51.5% were male, 48.5% were female, 11.0% were Hispanic or Latino; 84.1% were White, 2.7% were African American, 6.3% were Asian, 0.5% were American Indian or Alaska Native, <0.1% were Native Hawaiian or Pacific Islander, 0.9% were other races, and 4.8% were Multiracial. Between participants who received Moderna COVID-19 Vaccine and those who received placebo, there were no notable differences in demographics.

The median length of follow up for efficacy for participants in the study was 53 days post Dose 2.

The efficacy information in adolescents 12 years through 17 years of age is presented in Table 9.



**Table 9: Efficacy Analyses: COVID-19 in Participants 12 Years Through 17 Years of Age Starting 14 Days After Dose 2 – Per-Protocol Set for Efficacy**

	Moderna COVID-19 Vaccine N=2,139		Placebo N=1,042		% Vaccine Efficacy (95% CI)*
	COVID-19 Cases (n)	Incidence Rate of COVID-19 per 1,000 Person-Years	COVID-19 Cases (n)	Incidence Rate of COVID-19 per 1,000 Person-Years	
<b>COVID-19 Case Definition 1<sup>a</sup></b>	0	0	4	16.525	100.0 (28.9, NE)
<b>COVID-19 Case Definition 2<sup>b</sup></b>	1	1.939	7	28.981	93.3 (47.9, 99.9)

NE = Not estimable

\* Vaccine efficacy defined as  $1 - \text{ratio of incidence rate (Moderna COVID-19 Vaccine vs. placebo)}$ . The 95% CI of the ratio is calculated using the exact method conditional upon the total number of cases, adjusting for person-years.

<sup>a</sup> COVID-19 Case Definition 1: Participant must have experienced at least two of the following systemic symptoms: fever ( $\geq 38^\circ\text{C}$  /  $\geq 100.4^\circ\text{F}$ ), chills, myalgia, headache, sore throat, new olfactory and taste disorder(s); or the participant must have experienced at least one of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing, or clinical or radiographical evidence of pneumonia; and the participant must have at least one NP swab, nasal swab, or saliva sample (or respiratory sample, if hospitalized) positive for SARS-CoV-2 by RT-PCR.

<sup>b</sup> COVID-19 Case Definition 2: Presence of at least one symptom from a list of COVID-19 symptoms and a positive NP swab or saliva sample for SARS-CoV-2 by RT-PCR. Listed symptoms were fever (temperature  $> 38^\circ\text{C}$  /  $\geq 100.4^\circ\text{F}$ ), or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle aches, or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea, or vomiting or diarrhea.

### 18.3 Immunogenicity of a Third Primary Series Dose in Individuals with Certain Kinds of Immunocompromise

An independent randomized-controlled study has been conducted in 120 adult participants who had undergone various solid organ transplant procedures (heart, kidney, kidney-pancreas, liver, lung, pancreas) a median of 3.57 years previously (range 1.99-6.75 years). A third 0.5 mL primary series dose of the Moderna COVID-19 Vaccine was administered to 60 participants approximately 2 months after they had received a second dose; saline placebo was given to 60 individuals for comparison. Significant increases in levels of SARS-CoV-2 antibodies occurred four weeks after the third dose in 55.0% of participants in the Moderna COVID-19 Vaccine group (33 of 60) and 17.5% of participants in the placebo group (10 of 57).

### 18.4 Immunogenicity of a First Booster Dose Following a Moderna COVID-19 Vaccine Primary Series in Participants 18 Years and Older

Effectiveness of a booster dose of the Moderna COVID-19 Vaccine was based on assessment of neutralizing antibody titers (ID50) against a pseudovirus expressing the SARS-CoV-2 Spike protein from a USA\_WA1/2020 isolate carrying the D614G mutation. Immunogenicity analyses compared the ID50 following the booster dose to the ID50 following the primary series.

In an open-label phase of Study 2, participants 18 years of age and older received a single booster dose (0.25 mL) at least 6 months after completion of the primary series (two doses of 0.5 mL 1 month apart). The primary immunogenicity analysis population included 149 booster dose participants in Study 2 (including one individual who had only received a single dose of the primary series) and a random subset of 1,055 participants from Study 1 who received two doses (0.5 mL 1 month apart) of Moderna COVID-19 Vaccine. Study 1 and 2 participants included in the analysis population had no serologic or virologic evidence of SARS-CoV-2 infection prior to the first primary series dose and prior to the booster dose, respectively. Among participants assessed for immunogenicity, 60.4% were female, 6.7% were Hispanic or Latino; 95.3% were White, 3.4% were Black or African American, 0.7% were Asian, and 0.7% were American Indian or Alaskan Native; 9.4% were obese (body mass index  $\geq 30$  kg/m<sup>2</sup>). The median age of Study 2 participants was 56 years of age (range 18-82) and 24.8% of participants were 65 years of age and older. Study 2 participants included in the primary immunogenicity analysis population did not have pre-existing medical conditions that would place them at risk of severe COVID-19. Study 1 participants included in the primary immunogenicity analysis population were a stratified random sample which reflected the overall primary efficacy analysis population with regards to demographics and pre-existing medical conditions with a higher percentage of those  $\geq 65$  years of age (33.6%), with risk factors for severe COVID-19 (39.4%), and communities of color (53.5%).

Immunogenicity analyses included an assessment of ID50 geometric mean titer (GMT) ratio and difference in seroresponse rates. The analysis of the GMT ratio of ID50 following the booster dose compared to the primary series met the immunobridging criteria for a booster response. Seroresponse for a participant was defined as achieving a  $\geq 4$ -fold rise in ID50 from baseline (before the booster dose in Study 2 and before the first dose of the primary series in Study 1). The lower limit of the 2-sided 95% CI for the difference in seroresponse rates between Study 1 and Study 2 was -16.7%, which did not meet the immunobridging criterion for a booster response (lower limit of 2-sided 95% CI for the percentage difference of  $\geq -10\%$ ). These analyses are summarized in Table 10 and Table 11.

**Table 10: Neutralizing Antibody Geometric Mean Titers (ID50) Against a Pseudovirus Expressing the SARS-CoV-2 Spike Protein (USA\_WA1/2020 isolate carrying the D614G mutation) at 28 Days After a Booster Dose in Study 2 vs 28 Days After Completion of the Primary Series in Study 1, Participants  $\geq 18$  Years of Age, Per-Protocol Immunogenicity Set\***

Study 2 Booster Dose N <sup>a</sup> =149 GMT <sup>b</sup> (95% CI)	Study 1 Primary Series N <sup>a</sup> =1053 GMT <sup>b</sup> (95% CI)	GMT Ratio (Study 2/Study 1)	Met Success Criteria <sup>c</sup>
1802 (1548, 2099)	1027 (968, 1089)	1.8 (1.5, 2.1)	Lower limit of 95% CI $\geq 0.67$ Criterion: Yes Point Estimate $\geq 1.0$ Criterion: Yes

\* Per-Protocol Immunogenicity Set included all subjects who had both baseline (or Study 2 Day 1 for Study 2) and post-vaccination immunogenicity samples, did not have SARS-CoV-2 infection at baseline (or Study 2 Day 1 for Study 2), did not have a major protocol deviation that impacted immune response, and had post-injection immunogenicity assessment at timepoint of primary interest (Day 29 for Study 2 and Day 57 for Study 1).

<sup>a</sup> Number of subjects with non-missing data at the corresponding timepoint.

<sup>b</sup> Given the lack of randomization in Study 2, the statistical analysis plan pre-specified an analysis of covariance model for estimating the geometric mean titer that adjusts for differences in age groups (<65 years, ≥65 years).

<sup>c</sup> Immunobridging is declared if the lower limit of the 2-sided 95% CI for the GMR is >0.67 and the point estimate of the GLSM ratio is ≥1.0.

Note: Antibody values < the lower limit of quantitation (LLOQ) are replaced by  $0.5 \times \text{LLOQ}$ . Values > the upper limit of quantitation (ULOQ) are replaced by the ULOQ if actual values are not available.

GLSM = Geometric least squares mean

GMR = Geometric mean ratio

**Table 11: Seroresponse Rates Against a Pseudovirus Expressing the SARS-CoV-2 Spike Protein (USA\_WA1/2020 isolate carrying the D614G mutation) at 28 Days Post-Booster Dose in Study 2 and 28 Days After Completion of the Primary Series in Study 1, Participants ≥18 Years of Age, Per-Protocol Immunogenicity Set\***

Study 2 Booster Seroresponse <sup>a</sup> N <sup>b</sup> =149 n (%) (95% CI) <sup>c</sup>	Study 1 Primary Series Seroresponse <sup>a</sup> N <sup>b</sup> =1050 n (%) (95% CI) <sup>c</sup>	Difference in Seroresponse Rate (Study 2-Study 1) % (95% CI) <sup>d</sup>	Met Success Criterion <sup>e</sup>
131 (87.9) (81.6, 92.7)	1033 (98.4) (97.4, 99.1)	-10.5 (-16.7, -6.1)	Lower limit of 95% CI ≥-10% Criterion: No

\* Per-Protocol Immunogenicity Set included all subjects who had both baseline (or Study 2 Day 1 for Study 2) and post-vaccination immunogenicity samples, did not have SARS-CoV-2 infection at baseline (or Study 2 Day 1 for Study 2), did not have a major protocol deviation that impacted immune response, and had post-injection immunogenicity assessment at timepoint of primary interest (Day 29 for Study 2 and Day 57 for Study 1).

<sup>a</sup> Seroresponse is defined as ≥4-fold rise of pseudovirus neutralizing antibody titers (ID50) from baseline (pre-booster dose in Study 2 and pre-Dose 1 in Study 1), where baseline titers < LLOQ are set to LLOQ for the analysis.

<sup>b</sup> Number of subjects with non-missing data at both baseline and the post-baseline timepoint of interest.

<sup>c</sup> 95% CI is calculated using the Clopper-Pearson method.

<sup>d</sup> 95% CI is calculated using the Miettinen-Nurminen (score) confidence limits.

<sup>e</sup> Immunobridging is declared if the lower limit of the 2-sided 95% CI for the percentage difference is > -10%.

Study 2 participants who met the ≥4-fold increase in titer post-booster dose (87.9%) had a lower baseline GMT of 109 (range of individual titers 9, 4393), whereas Study 2 participants who did not meet the ≥4-fold increase in titers post-booster had a higher baseline GMT of 492 (range of individual titers 162, 2239).

An additional descriptive analysis evaluated seroresponse rates using baseline neutralizing antibody titers prior to Dose 1 of the primary series. As shown in Table 12 below, the booster dose seroresponse rate, with seroresponse defined as at least a 4-fold rise relative to the pre-Dose 1 titer, was 100%. The difference in seroresponse rates in this post-hoc analysis was 1.6% (95% CI -0.9, 2.6).

**Table 12: Analysis of Seroresponse Rates Against a Pseudovirus Expressing the SARS-CoV-2 Spike Protein (USA\_WA1/2020 isolate carrying the D614G mutation) at 28 Days Post-Booster Dose in Study 2 and 28 Days After Completion of the Primary Series in Study 1, Participants  $\geq 18$  Years of Age, Per-Protocol Immunogenicity Set\***

<b>Study 2 Booster Seroresponse<sup>a</sup> N<sup>b</sup>=148 n (%) (95% CI)<sup>d</sup></b>	<b>Study 1 Primary Series Seroresponse<sup>a</sup> N<sup>c</sup>=1050 n (%) (95% CI)<sup>d</sup></b>	<b>Difference in Seroresponse Rate (After Booster-After Primary Series) % (95% CI)<sup>e</sup></b>
148 (100) (97.5, 100)	1033 (98.4) (97.4, 99.1)	1.6 (-0.9, 2.6)

\* Per-Protocol Immunogenicity Set included all subjects who had non-missing data at baseline (before Dose 1) and 28 days post-booster in Study 2 or 28 days post-Dose 2 in the primary series in Study 1, respectively, did not have SARS-CoV-2 infection at pre-booster in Study 2 or baseline in Study 1, did not have a major protocol deviation that impacted immune response, and had post-injection immunogenicity assessment at timepoint of primary interest.

<sup>a</sup> Seroresponse is defined as  $\geq 4$ -fold rise of pseudovirus neutralizing antibody titers (ID50) from pre-Dose 1, where baseline titers < LLOQ are set to LLOQ for the analysis.

<sup>b</sup> Number of subjects with non-missing data at baseline (before Dose 1) and 28 days post-booster in Study 2.

<sup>c</sup> Number of subjects with non-missing data at baseline (before Dose 1) and 28 days post-Dose 2 in the primary series in Study 1.

<sup>d</sup> 95% CI is calculated using the Clopper-Pearson method.

<sup>e</sup> 95% CI is calculated using the Miettinen-Nurminen (score) confidence limits.

### **18.5 Immunogenicity of a First Booster Dose Following Primary Vaccination with Another Authorized or Approved COVID-19 Vaccine**

Effectiveness of a Moderna COVID-19 Vaccine booster dose (0.25 mL) in individuals who completed primary vaccination with another authorized or approved COVID-19 vaccine (heterologous booster dose) is inferred from immunogenicity data supporting effectiveness of a Moderna COVID-19 Vaccine (0.25 mL) booster dose administered following completion of a Moderna COVID-19 Vaccine primary series and from immunogenicity data from an independent Phase 1/2 open-label clinical trial (NCT04889209) conducted in the United States that evaluated a booster dose (0.5 mL) of the Moderna COVID-19 Vaccine. In this study, adults who had completed primary vaccination with a Moderna COVID-19 Vaccine 2-dose series (N=151), a Janssen COVID-19 Vaccine single dose (N=156), or a Pfizer-BioNTech COVID-19 Vaccine 2-dose series (N=151) at least 12 weeks (range 12 to 20 weeks) prior to enrollment and who reported no history of SARS-CoV-2 infection were randomized 1:1:1 to receive a booster dose of one of three vaccines: Moderna COVID-19 Vaccine, Janssen COVID-19 Vaccine, or Pfizer-BioNTech COVID-19 Vaccine. Neutralizing antibody titers, as measured by a pseudovirus neutralization assay using a lentivirus expressing the SARS-CoV-2 Spike protein with D614G mutation, were assessed on Day 1 prior to administration of the booster dose and on Day 15 after the booster dose. A booster response to the Moderna COVID-19 Vaccine (0.5 mL) was demonstrated regardless of the vaccine used for primary vaccination.

## 18.6 Immunogenicity of a Second Booster Dose

Immunogenicity data from an ongoing, open-label, non-randomized clinical study in healthcare workers at a single center in Israel were provided in a publication (*Gili Regev-Yochay, Tal Gonen, Mayan Gilboa, et al. 2022 DOI: 10.1056/NEJMc2202542*). In this study, 120 individuals 18 years of age and older who had received primary vaccination and a first booster dose with Pfizer-BioNTech COVID-19 Vaccine were administered a second booster dose of Moderna COVID-19 Vaccine at least 4 months after the first booster dose. Among these individuals, approximately 7- to 16-fold increases in geometric mean neutralizing antibody titers against wild-type virus and Delta and Omicron variants were reported at two weeks after the second booster as compared to 5 months after the first booster dose.

## 19 HOW SUPPLIED/STORAGE AND HANDLING

The information in this section applies to the Moderna COVID-19 Vaccine that is supplied in multiple-dose vials with red caps and labels with a light blue border. These multiple-dose vials are supplied as follows:

NDC 80777-273-99 Carton of 10 multiple-dose vials, each vial containing 5.5 mL  
NDC 80777-273-98 Carton of 10 multiple-dose vials, each vial containing 7.5 mL

During storage, minimize exposure to room light, and avoid exposure to direct sunlight and ultraviolet light.

### Frozen Storage

Store frozen between -50°C to -15°C (-58°F to 5°F).

### Storage after Thawing

- Storage at 2°C to 8°C (36°F to 46°F):
  - Vials may be stored refrigerated between 2°C to 8°C (36°F to 46°F) for up to 30 days prior to first use.
  - Vials should be discarded 12 hours after the first puncture.
- Storage at 8°C to 25°C (46°F to 77°F):
  - Vials may be stored between 8°C to 25°C (46°F to 77°F) for a total of 24 hours.
  - Vials should be discarded 12 hours after the first puncture.
  - Total storage at 8°C to 25°C (46°F to 77°F) must not exceed 24 hours.

### **Do not refreeze once thawed.**

Thawed vials can be handled in room light conditions.

### Transportation of Thawed Vials at 2°C to 8°C (36°F to 46°F)

If transport at -50°C to -15°C (-58°F to 5°F) is not feasible, available data support transportation of one or more thawed vials for up to 12 hours at 2°C to 8°C (36°F to 46°F) when shipped using shipping containers which have been qualified to maintain 2°C to 8°C (36°F to 46°F) and under

routine road and air transport conditions with shaking and vibration minimized. Once thawed and transported at 2°C to 8°C (36°F to 46°F), vials should not be refrozen and should be stored at 2°C to 8°C (36°F to 46°F) until use.

## **20 PATIENT COUNSELING INFORMATION**

Advise the recipient or caregiver to read the Vaccine Information Fact Sheet for Recipients and Caregivers.

The vaccination provider must include vaccination information in the state/local jurisdiction's Immunization Information System (IIS) or other designated system. Advise recipient or caregiver that more information about IISs can be found at:

<https://www.cdc.gov/vaccines/programs/iis/about.html>.

## **21 CONTACT INFORMATION**

For general questions, send an email or call the telephone number provided below.

<b>Email</b>	<b>Telephone number</b>
<a href="mailto:medinfo@modernatx.com">medinfo@modernatx.com</a>	1-866-MODERNA (1-866-663-3762)

This EUA Prescribing Information may have been updated. For the most recent Full EUA Prescribing Information, please visit [www.modernatx.com/covid19vaccine-eua](http://www.modernatx.com/covid19vaccine-eua).

Moderna US, Inc.  
Cambridge, MA 02139

©2022 ModernaTX, Inc. All rights reserved.

Patent(s): [www.modernatx.com/patents](http://www.modernatx.com/patents)

Revised: June/17/2022